

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 513 379 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
11.09.1996 Bulletin 1996/37

(21) Application number: 91920699.5

(22) Date of filing: 29.11.1991

(51) Int. Cl.⁶: A61K 31/425, A61K 31/44

(86) International application number:
PCT/JP91/01670

(87) International publication number:
WO 92/09279 (11.06.1992 Gazette 1992/13)

(54) 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

2-ARYLTHIAZOLDERIVAT SOWIE DIESES ENTHALTENDES ARZNEIMITTEL

DERIVE DE 2-ARYLTHIAZOLE ET COMPOSITION PHARMACEUTIQUE CONTENANT CE DERIVE

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IT LI NL SE

(30) Priority: 30.11.1990 JP 330147/90
02.08.1991 JP 216586/91

(43) Date of publication of application:
19.11.1992 Bulletin 1992/47

(73) Proprietor: TEIJIN LIMITED
Osaka-shi Osaka 541 (JP)

(72) Inventors:
• KONDO, Shiro
2-10-4-305, Bessho
Tokyo 192-03 (JP)
• FUKUSHIMA, Hisashi
12, Teijin toyoda-Apart.
Hino-shi Tokyo 191 (JP)
• HASEGAWA, Masaichi
6, Teijin toyoda-Apart.
Hino-shi Tokyo 191 (JP)
• TSUCHIMOTO, Masahiro
101, Marukoh-Corp.
Hino-shi Tokyo 191 (JP)
• NAGATA, Ikuo
201, Central Heights Shinmei
Hino-shi Tokyo 191 (JP)
• OSADA, Yoshio
Teijin Musashino-ryo
Hino-shi Tokyo 191 (JP)
• KOMORIYA, Keiji
1532-117, Uchikoshi-cho
Tokyo 192 (JP)

• YAMAGUCHI, Hisao
2-2-12, Asahigaoka
Tokyo 191 (JP)

(74) Representative: Harrison, Ivor Stanley
Withers & Rogers
4 Dyer's Buildings
Holborn
London EC1N 2JT (GB)

(56) References cited:
EP-A- 0 033 151 WO-A-90/09381
WO-A-90/09801 DE-A- 2 125 193
DE-A- 2 125 251 DE-A- 3 026 054
DE-A- 3 141 430 JP-A- 2 229 190
JP-A-59 016 889 JP-A-62 178 590

• PATENT ABSTRACTS OF JAPAN, vol. 12, no. 358
(C-531), 26th September 1988; & JP-A-63 112 574
(YAMANOUCHI PHARMACEUT. CO., LTD) 17-05-
1988
• PATENT ABSTRACTS OF JAPAN, vol. 12, no. 358
(C-531), 26th September 1988; & JP-A-63 112 572
(YAMANOUCHI PHARMACEUT. CO., LTD) 17-05-
1988
• Therapie, Vol. 26, No. 3 (1971), LECHAT P. et al.
"Comparison of the hypolipemic effect of
nicotinic acid and some substituted thiazole
acids". p. 497-509
• Ann. Chim., Vol. 64, Nos. 7 to 8 (1974),
TORNETTA BENEDETTO et al. "Reactions
between thiobenzamides and ethyl beta-
chloroacetoneoxalate. Synthesis of thiazole,
thiazolooxazine, and thiazolopyridazine
derivatives". p. 477-84

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

TECHNICAL FIELD

The present invention relates to 2-arylthiazole derivatives or their pharmaceutically acceptable salts, and pharmaceutical compositions containing the same, and in particular, to the use thereof for treating gout or hyperuricemia, or diseases associated with a production of interleukin 1.

BACKGROUND ART

It is recognized that human beings among animals, especially adult men, suffer from gout derived from hyperuricemia, including a lesion of renal stroma, blood vessels, urinary calculus, acute arthritis and gouty tophus caused by lithogenesis.

In the treatment of the gout, colchicine or a non-steroidal anti-inflammatory drug is used during the acute arthritic attack, and an hypouricemic therapy for hyperuricemia is conducted after a remission of the attack. The therapeutic agent for hyperuricemia is roughly classified into a uricosuric accelerator and a uricopiesis inhibitor, which can be properly selected depending upon the conditions and severity of diseases. Examples of the former include probenecid and benzbromarone. Allopurinol, which is a structural isomer of hypoxanthine, has long been used as the latter. Allopurinol inhibits xanthine oxidase and prevents the formation of uric acid from hypoxanthine and xanthine, to thus lower the serum uric acid level. Although the enzyme inhibitors of this type have been widely studied, using xanthine derivatives in the main, no drug has yet been found to safety requirements, and only allopurinol is applied to alleviate gout. Japanese Unexamined Patent Publication (Kokai) Nos. 57-85379 and 59-95272 disclose that isothiazole and a pyrazole derivatives inhibit xanthine oxidase to lower the serum uric acid level in mammal, but to date, none are in use for clinical applications.

On the other hand, a variety of 2-arylthiazole derivatives, and their synthetic intermediates has been proposed to have various physiological activities such as anti-inflammatory, analgesic, antimicrobial and antitumor activities, and inhibitory activity for prolyl or lysylhydroxylase. Also, it is known that 2-arylthiazole derivatives are used in the dye art. Among the known compounds, 2-arylthiazole derivatives having a methylcarboxyl group ($-\text{CH}_2\text{COOH}$ or its ester) at the 5- or 4-position of the thiazole ring have been found to possess anti-inflammatory or analgesic action, the compounds are studied in the art (see, for example, Spanish Patent No. 499110, GB Patent No. 687981 or Japanese Examined Patent Publication (Kokoku) No. 43-19307, GB Patent No. 1137529 or Japanese Examined Patent Publication (Kokoku) No. 47-41353, GB Patent No. 1145884 or Japanese Examined Patent Publication (Kokoku) No. 49-38267, DE-A-1917432 or Japanese Examined Patent Publication (Kokoku) No. 47-7368, GB Patent No. 1574583, BE Patent No. 888252). In synthetic intermediates or final products of the other physiologically active substances or dyes, there are included 2-arylthiazole derivatives having a carboxyl group, or either an ester or amide group derived at a 4- or 5-position in a thiazole ring thereof, for example, A. Benko et al., Chem. Ber. **100**, (1967) 7, 2184-87, discloses 4-methyl-2-phenyl-5-thiazolecarboxylic acid and m-nitro or p-nitro substituted compounds on a phenyl group thereof; DE-A-3026054 or Japanese Examined Patent Publication (Kokoku) No. 63-10701, and Japanese Examined Patent Publication (Kokoku) No. 63-10950 disclose 2-phenyl-5-thiazolecarboxylic acid derivatives in which the 2-phenyl moiety has three methoxy groups for antiulcer; DE-A-1959307 discloses a variety of dyes prepared from 2-phenyl-5-thiazole carboxylic acid as a starting material; DE-A-3141430, DE-A-2125193 and DE-A-2125251 disclose 2-phenyl-5-thiazolecarboxylic acid derivatives in which the 2-phenyl moiety is tri-substituted by nitro, amino and azo groups, as used for dye and synthetic intermediates thereof; US Patent No. 3518279 discloses, as used for synthetic intermediates of an insecticide, 2-phenyl-5-thiazolecarboxylic acid derivatives in which the 2-phenyl moiety has substituent(s) such as a halogen atom, lower-alkyl, alkoxyl, alkylamino or acylamino group, and further, has a carboxylic ester residue at a 5-position of same; and DE-C-3002989 discloses 2-phenyl-4-thiazole-carboxylic acid derivatives in which the 2-phenyl moiety has a hydroxyl group at a 2'-position, a hydrogen atom, methyl group, halogen atom, nitro group, amino group or sulfonamide group at a 3'- or 5'-position, and a hydrogen atom, hydroxyl or methyl group at a 4'-position of same, as an inhibitor of prolyl- or lysyl-hydroxylase.


Furthermore, in a synthetic investigation of thiazole derivatives, 2-aryl-5-thiazolecarboxylic acid derivatives are disclosed as intermediates (for example, Arch. Pharm. (Weinheim) **309** (1976) 2, 128-130).

WO-A-90/09801 and WO-A-90/09381 disclose various substituted 4-hydroxythiazoles as inhibitors of lipoxigenase enzymes, the compounds thereby reducing the biosynthesis of leukotrienes and alleviating the symptoms of a variety of conditions, including gout, by reducing inflammation. However, in the prior art, it is neither described nor suggested that 2-arylthiazole derivatives may have a xanthine oxidase inhibitory activity or uric acid-decreasing activity, or an inhibitory activity to production of interleukin 1 or arthritis associated with the production of same.

DISCLOSURE OF THE INVENTION

The present inventors have made extensive and intensive researches into the provision of a useful compound as a xanthine oxidase inhibitor, from a different viewpoint to that of prior investigations into the inhibitor and, as a result, have accomplished the present invention based upon a finding that some 2-arylthiazole derivatives have a high xanthine oxidase inhibitory activity or uric acid decreasing action, and thus are efficacious against gout or hyperuricemia, and further, have a high inhibitory activity against the production of interleukin 1.


Therefore, in accordance with the present invention, pharmaceutical compositions comprising an effective amount of a 2-arylthiazole derivative having the following formula (I) or pharmaceutically acceptable salts thereof for treating diseases selected from the group consisting of gout or hyperuricemia and diseases associated with the production of interleukin 1, are provided:



(I)

wherein

Ar represents an unsubstituted or substituted pyridyl, thienyl, furyl or naphthyl group, or a group having the following formula (II)



(II)

wherein

at least one group of R_1 , R_2 and R_3 is hydrogen or a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR , $S(O)_nR$ and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R' , taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), or a group of COR'' (wherein R'' represents an unsubstituted or substituted C_{1-10} alkyl, aryl or aralkyl group; a hydroxyl group; an unsubstituted or substituted C_{1-10} alkoxy, aryloxy or aralkyloxy group; an amino group; or an unsubstituted or substituted C_{1-10} alkyl (mono- or di-substituted, independently) amino, aryl (mono- or di-substituted, independently) amino or aralkyl (mono- or di-substituted, independently) amino group, or a 5- to 7- membered cyclic amino group);

X represents a hydrogen atom, or a C_{1-4} alkyl, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group; and

Y represents a hydrogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group,


with the proviso that when at least one group of R_1 , R_2 and R_3 represents a halogen atom, or an alkoxy, alkylamino or nitro group, at least one group of the two other groups represents a group other than hydrogen; when at least one group of R_1 , R_2 and R_3 is a halogen atom and another group is a hydrogen atom, the remaining group is a group other than a halogen, or an alkoxy, alkylamino or acylamino group; and R_1 , R_2 and R_3 are not all methoxy at the same time.

Furthermore, in accordance with the present invention, novel compounds according to the formula (I) are provided.

BEST MODE OF CARRYING OUT THE INVENTION

Each group of the 2-arylthiazole derivative according to the present invention is particularly disclosed below.

Ar is an unsubstituted or substituted pyridyl, thienyl, furyl or naphthyl group; or a group represented by the following formula (II)



10 wherein

R_1 , R_2 and R_3 are as defined above.

According to the above-described definition, substituents which may have further substituent(s), i.e., pyridyl, thienyl, furyl or naphthyl group; C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; 5- to 7-membered heterocyclic ring; C_{1-10} alkoxy, aryloxy or aralkyloxy group; and C_{1-10} alkyl (mono- or di-substituted) amino, aryl (mono- or di-substituted) amino group, on chain or cyclic moiety thereof, are substituted by one or more C_{1-4} alkyl, halogenated alkyl, carboxyl, alkylcarbonyl, alkyloxy, alkylcarbonyloxy, hydroxyl, mono- or di-substituted alkylamino, amino, nitro, cyano or formyl group, or halogen atom (e.g., fluorine, chlorine, bromine, iodine), heterocyclic ring such as 5- to 7- membered cyclic-secondary amino group, etc.. Preferred groups of such substituents are a halogen atom, methyl group, ethyl group, methoxy group and ethoxy group.

Examples of the halogen atom include fluorine, chlorine, bromine and iodine atoms, as described above, and chlorine and fluorine are preferred. Examples of the C_{1-4} alkyl group include methyl group, ethyl group, (iso- or n-)propyl group and (iso-, n-, tert- or sec-)butyl group, and a methyl group and a tert-butyl group are preferred. Examples of the C_{1-4} haloalkyl group include a haloalkyl group comprising the above-described halogen atom and alkyl group, and a trifluoromethyl group is preferred.

In the present invention, the term " C_{1-10} alkyl group" as R, R' and R" is intended to mean a C_{1-10} straight-chain or branched aliphatic hydrocarbon residue, cyclic aliphatic hydrocarbon residue or chain-cyclic aliphatic hydrocarbon residue, and examples thereof include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, n-octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclohexylmethyl, cyclohexylpropyl, methoxyethyl, ethoxyethyl, and the like.

Examples of the aryl group include aromatic hydrocarbon residues or aromatic heterocyclic ring groups comprising 5- or 6-membered monocyclic or fused ring, for example, phenyl, 1-naphthyl, 2-naphthyl, 2-pyrrolyl, 2-furyl, 2-thienyl, 2-pyridyl, and the like.

The aralkyl group is a group comprising the above-described lower alkyl or aryl group having a number of constituent atoms of 6 to 10 and aryl group, and examples thereof include lower aralkyl groups such as benzyl, 1-phenylethyl, 1-methyl-1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, cinnamyl, 2-pyrrolylmethyl, furfuryl, thenyl, and the like, and a benzyl group is preferred.

In the present invention, the alkylcarbonyl group is a group comprising the above-described lower alkyl group and a carbonyl group, and examples thereof include C_{2-7} lower aliphatic acyl groups such as acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2-methylbutanoyl, 3-methylbutanoyl, pivaloyl, hexanoyl, cyclopropylcarbonyl, and the like. The arylcarbonyl group is a group comprising the above-described aryl group and a carbonyl group, and examples thereof include benzoyl, toluoyl, 2-pyrrolylcarbonyl, 2-fluoyl, 2-thiophenecarbonyl, and the like. The aralkylcarbonyl group is a group comprising the above-described aralkyl group and a carbonyl group, and examples thereof include C_{5-10} aralkylcarbonyl groups such as phenylacetyl, 3-phenylpropanoyl, 4-phenylbutanoyl, cinnamoyl, 2-pyrrolylacetyl, 2-furylacetyl, 2-thienylacetyl, and the like.

According to the above-described definition of R, examples of OR include ethoxy, (n- or iso-)propoxy, (n-, iso-, sec- or tert-)butoxy, pentyloxy, n-hexyloxy, cyclopropylmethyloxy, cyclohexyloxy, phenyloxy, benzyloxy, phenetyloxy, methoxyethyloxy, ethoxyethyloxy, acetoxo, propanoyloxy, butanoyloxy, benzoyloxy, and the like.

According to the above-described definition of R, examples of the $S(O)_n$ R include ethylthio, isopropylthio, isopropylsulfinyl, isopropylsulfonyl, pentylsulfonyl, phenylthio, phenylsulfinyl, phenylsulfonyl, and the like.

According to the above-described definition of R and R', examples of the NRR' include dimethylamino, diethylamino, benzylamino, phenethylamino, and the like, and where R and R' taken together with each other nitrogen atom bonded thereof, represent atoms to form an unsubstituted or substituted 5- to 7-membered heterocyclic ring, examples of the heterocyclic ring include morpholino, 1-pyrrolyl, 1-pyrrolidinyl, piperidino, piperazino, and the like.

According to the above-described definition of R", when R" is a C_{1-10} alkoxy group of the COR", R" is a group comprising the above-described alkyl group and an oxy group, and for example, includes methoxy, ethoxy, (n- or iso-)propoxy, (n-, iso-, sec- or tert-)butoxy, 3-methylbutoxy, 2-ethylbutoxy, pentyloxy, hexyloxy, 3-methyl-2-butenyloxy, geranyloxy, cyclopentyloxy, cyclohexyloxy, cyclohexyl- C_{1-4} -alkyloxy (e.g., cyclohexylmethyloxy), and the like.

The aryloxy group comprise the above-described aryl group and an oxy group, and examples thereof include phenoxy, 1-naphthoxy, and the like. The aralkyloxy group comprises the above-described aralkyl group and an oxy group,

and for example, includes benzyloxy, 1-phenylethoxy, 1-methyl-1-phenylethoxy, and the like. The C_{1-10} alkyl(mono- or di-substituted)amino group comprises the above-described alkyl group and an amino group, and examples thereof include methylamino, ethylamino, dimethylamino, diethylamino groups, and the like. The aryl(mono- or di-substituted)amino group comprises the above-described aryl group and an amino group, and examples thereof include phenylamino, methylphenylamino, and the like. The aralkyl(mono- or di-substituted)amino group comprises the above-described aralkyl group and an amino group, and examples thereof include benzylamino, methylbenzylamino, and the like. Examples of the 5- to 7- membered cyclic-secondary amino group include morpholino, 1-pyrrolyl, 1-pyrrolidino, piperidino, and the like.


In the X and Y of the formula (I), the C_{1-4} alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, and the like; the C_{1-5} alkoxy carbonyl group is an alkoxy carbonyl in which the alkyl moiety has the above-described alkyl, and include, for example, methoxycarbonyl, ethoxycarbonyl, (n- or iso-) propoxycarbonyl or (n-, iso-, sec- or tert-)butoxy(or butyloxy)carbonyl; and the C_{1-4} alkyl (mono- or di-substituted)aminocarbonyl group includes, for example, methylaminocarbonyl, ethylaminocarbonyl, dimethylaminocarbonyl, and the like.

The derivatives of the formula (I) used for the object of the invention, where the above-described substituent is a carboxyl group, can form a pharmaceutically acceptable salt together with non-toxic cations which will be described later, for example, sodium, potassium, and the like, or can be provided in the form of prodrug, and these salts and prodrugs can be used in the same manner as a free compound of the formula (I), respectively.

In accordance with the present invention, novel compounds within the above-described definition of 2-arylthiazole derivatives having the formula (I), which are novel and in which each substituent is defined as described below, are provided. Namely, there are provided 2-arylthiazole derivatives having the formula (I):

wherein

Ar is an unsubstituted or substituted pyridyl, thienyl, furyl or naphthyl group; or a group represented by the following formula (II)



(II)

wherein

at least one group of R_1 , R_2 and R_3 is a hydrogen or halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR, $S(O)_nR$ and NRR' (wherein n is an integer from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereof, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), or a group of COR'' (wherein R'' represents an unsubstituted or substituted C_{1-10} alkyl, aryl or aralkyl group; a hydroxyl group; an unsubstituted or substituted C_{1-10} alkoxy, aryloxy or aralkyl-oxy group; an amino group; or an unsubstituted or substituted C_{1-10} alkyl(mono- or di-substituted, independently)amino, aryl(mono- or di-substituted, independently)amino or aralkyl(mono- or di-substituted, independently)amino group, or a 5- to 7- membered cyclic amino group);

X represents a hydrogen atom, or a C_{1-4} alkyl, carboxyl, C_{1-5} alkoxy carbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted)aminocarbonyl group; and

Y represents a hydrogen atom, or a C_{1-4} alkyl, C_{1-4} alkoxy, carboxyl, C_{1-5} alkoxy carbonyl, carbamoyl or C_{1-4} alkyl(mono- or di-substituted) aminocarbonyl group,

with the proviso that when at least one group of R_1 , R_2 and R_3 represents a halogen atom, or a alkoxy, alkylamino or nitro group, at least one group of other two groups represents a group other than hydrogen atom; when at least one group of R_1 , R_2 and R_3 is a halogen atom and another group is a hydrogen atom, a remaining group is a group other than the halogen atom, or an alkoxy, alkylamino or acylamino group; and R_1 , R_2 and R_3 are not all methoxy at the same time; and pharmaceutically acceptable salts thereof.

Of these compounds, it is preferably the 2-arylthiazole derivatives are of the formula (I), wherein

Ar is a group representing the formula (II), and R_1 is a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; R_2 is a trifluoromethyl, or a group of OR, $S(O)_nR$ or NRR' (wherein n is an integer from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereto, represents atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring); and R_3 represents a hydrogen atom or a halogen atom;

X represents a carboxyl, C₁₋₅ alkoxy carbonyl, carbamoyl or C₁₋₄ alkyl (mono- or di-substituted) aminocarbonyl group; and


Y represents a hydrogen atom, or C₁₋₄ alkyl, C₁₋₄ alkoxy or carboxyl group; and pharmaceutically acceptable salts thereof.

Particularly, it is preferred that the 2-arylthiazole derivatives are of the formula (I) wherein,

Ar is a group representing the formula (II), and R₁ is a *m*-nitro group, R₂ is a group of OR, S(O)_nR and NRR' (wherein n is an integer from 0 to 2, R represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereof, represents atoms to form an unsubstituted or substituted 5- to 7- membered heterocyclic ring), and R₃ represents a hydrogen atom; or R₁ is a *m*-halogen atom, or a *m*-cyano or *m*-trifluoromethyl group, R₂ is a group of OR, S(O)_nR and NRR' (wherein n is an integer from 0 to 2, R represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl, R' represents a hydrogen atom, or an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereof, represents atoms to form an unsubstituted or substituted 5- to 7- membered heterocyclic ring), and R₃ is a hydrogen or halogen atom; or

R₁ is a group of COR'' (wherein R'' represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl or aralkyl group); X and Y are as defined above, respectively; and pharmaceutically acceptable salts thereof.

Of such derivatives, in particular, it is preferred that a 2-arylthiazole derivative is selected from a group consisting of compounds having the following formula (I-a):



(I - a)

wherein

R_{1-a} is a C₂₋₈ alkoxy group, and R_{2-a} is a nitro group;


R_{1-a} is a C₂₋₈ alkoxy group, and R_{2-a} is a trifluoromethyl group;

R_{1-a} is a C₂₋₈ alkoxy group, and R_{2-a} is a cyano group;

R_{1-a} is a morpholino, 4-N-methyl-piperazine-1-yl or piperidino, and R_{2-a} is a nitro, trifluoromethyl or cyano group; and

R_{1-a} is an unsubstituted or one or two of methyl, chloro or methoxy substituted benzoyl group, and R_{2-a} is a hydrogen atom, and a pharmaceutically acceptable salt thereof.

Alternatively, it is preferred that a 2-arylthiazole derivative is selected from a group consisting of compounds having the following formula (I-b):




(I - b)

wherein

R_{1-b} is a group of OR and SR (wherein R is a C₂₋₈ alkyl group) or a morpholino, 4-N-methyl-piperazine-1-yl or piperidino, R_{2-b} is a nitro, trifluoromethyl or cyano group, and Y_b is a hydrogen atom or a methyl group; and

R_{1-b} is a group of the formula




5

10 (wherein R_{3-b} is an unsubstituted or substituted phenyl group, R_{4-b} is a hydrogen atom, or a C_{1-3} alkyl group, and Y_b is a hydrogen atom or methyl group; and a pharmaceutically acceptable salt thereof.

Parts of the compounds hereinbefore set forth are well known in the art, and the novel compounds according to the present invention may be produced by a process of producing the known compound.

15 For example, the compounds can be generally prepared by known procedures as described in Organic Reactions, Vol. 6, 367-409(1951), or Heterocyclic Compounds, Vol. 34, (1978). Further, when Ar is represented by the formula (II), the compounds can be produced by the following process:



25

wherein R_1 , R_2 and R_3 are as defined above in connection with the formula (II), Y is as defined above in connection with the formula (I), Hal represents a halogen atom, and R_a represents a C_{1-4} alkyl group.

Specifically, a substituted thiobenzamide and an alkyl ester of 2-halogeno-acetylacetic acid are directly mixed or reacted with in solvent in the presence or absence of a base at a temperature in the range of room temperature to 200°C, preferably in the range of 50 to 100°C. Examples of the base include organic bases, such as triethylamine, pyridine and dimethylaminopyridine, and inorganic bases, such as anhydrous potassium carbonate and sodium hydroxide. The solvent may be any one as long as it has no adverse effect on the reaction, and examples thereof include hydrocarbons such as benzene, toluene and hexane, ethers such as dioxane and methylcellosolve, alcohols such as ethanol and isopropanol, and N,N-dimethylformamide, dimethylsulfoxide and acetonitrile. Among them, alcohols corresponding to the substituent R_a are preferred. The resultant ester derivative is hydrolyzed by a conventional process to provide a corresponding free acid.

The substituted thiobenzamide derivative is usually produced by adding phosphorus pentasulfide or a lawson reagent (see Bull. Soc. Chim. Belg. 87, 223 (1978)) from a corresponding benzamide in a solvent such as benzene.

40 It is also known that thiobenzamide is synthesized by adding hydrogen sulfide from a corresponding benzonitrile (see A.E.S. Fairfull et al., J. Chem. Soc., 1952, 742). Note, the addition of thioacetamide in N,N-dimethylformamide saturated with hydrochloric acid followed by heating (see E.C. Taylor et al., J. Am. Chem. Soc., 82, 2656 (1960)) is preferred from the viewpoint of yield, operating property and economy.

45 When a thiazole ring is formed, as described in Organic Synthesis III, 332 (1955) and Japanese Patent No. JP87055, an α -haloketone derivative may be allowed to react without isolation of a thioamide derivative or a thiobenzamide derivative.

When Ar is represented by a group other than the formula (II), an intended product can be produced in the same manner as that described above.

50 If necessary, the 2-aryl-5-thiazolecarboxylic acid derivative thus produced is converted to a salt thereof with a pharmaceutically acceptable non-toxic cation. Examples of this kind of cation include alkali metal cations such as Na and K, alkaline earth metal cations such as Mg and Ca, other metal cations used usually, such as Al and Zn and organic bases such as ammonia, triethylamine and pyridine. When the compounds represented by the formula (I) have an amino group in their molecule, they can be converted to corresponding acid addition salts. Examples of the acid include mineral acids such as hydrochloric acid, sulfuric acid and nitric acid and pharmaceutically acceptable organic acids such as acetic acid, benzoic acid, fumaric acid, maleic acid, methanesulfonic acid, toluenesulfonic acid or amino acids such as glycine and alanine.

55 The compounds produced in the present invention are provided in the form of oral preparations such as soft capsule, hard capsule, tablet, granule, powder, suspension, solution and syrup, injections, suppositories and external preparations by a conventional method through the use of a suitable excipient or the like. Examples of the excipient include

vegetable oils (for example, corn oil, cotton seed oil, coconut oil, almond oil, peanut oil, olive oil, and the like), oily esters such as medium-length chain fatty acid glyceride oil, mineral oils, glycerin esters such as tricaprylin, triacetin, and the like, alcohols such as ethanol, and the like, physiological saline, propylene glycol, polyethylene glycol, petrolatum, animal fat and oil, cellulose derivatives (crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose), polyvinyl pyrrolidone, dextrin, lactose, mannitol, sorbitol, starch, and the like.

The dose of the active ingredient is usually about 1 to 500 mg/day/person, preferably 10 to 300 mg/day/person, and it is preferred for formulations to be conducted so as to satisfy such a requirement.

The present inventors have found that the 2-arylthiazole derivatives of the formula (I) have very high xanthine oxidase inhibitory activity and serum uric acid lowering activity against mammals and surprisingly have a strong interleukin 1 (IL-1) production inhibitory activity. IL-1 is known to induce the activation of leucocytes, the sthenia of production of an antibody, the sthenia of production of cytokine and PGE₂ from macrophage, the dissolution of bone, the fever, etc., and is considered to participate in chronic rheumatism, osteoarthritis, osteoporosis, tissue rejection, sepsis, toxicogenic shock syndrome, symptoms such as fever and respiratory diseases derived from infection of virus or bacteria (i.e., "influenza"), chronic nephritis, secondary cachexia derived from malignant infection, keloplasty, cicatrization, Crohn's disease, colitis ulcerosa, multiple sclerosis and crisis and evolution of a reverse or other reaction against dialysis.

Therefore, the 2-arylthiazole derivatives etc. according to the present invention can be used as a therapeutic agent for gout or hyperuricemia, an interleukin 1 production inhibitor and a therapeutic agent for the above-described chronic inflammatory diseases such as nephritis, hepatitis and arthritis. Further, they can be expected to exhibit, as an interleukin 1 production inhibitor, a therapeutic effect quite different from that of the conventional antifebriles and anti-inflammatory agents and antiinfectants.

EXAMPLES

The following examples only illustrate the present invention and should not be interpreted as a limitation thereof.

Example 1

390 mg of 3-isopropoxythiobenzamide was dissolved in 5 ml of ethanol, 360 mg of ethyl 2-chloroacetoacetate was added to the solution, and the mixture was heated under reflux for five hours. After the reaction mixture was cooled, it was concentrated and subjected to silica gel chromatography (eluent, hexane: ethyl acetate = 9 : 1) to separate an intended product (490 mg). The resulting oily substance was dissolved in 5 ml of ethanol, 10 ml of a 1 N aqueous sodium hydroxide solution was added, and the mixture was heated at 70°C for one hour. After the completion of the reaction, ethanol was removed by distillation and the residue was neutralized with 1 N hydrochloric acid. The precipitated crystal was collected by filtration and recrystallized from a 50% aqueous ethanol solution to give 358 mg of 2-(3-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 65%).

m.p.: 177 - 179°C

¹H-NMR (CDCl₃) δ:

6.95 - 7.55 (m, 4H), 4.65 (m, 1H), 2.81 (s, 3H), 1.37 (d, 6H, J = 6.2 Hz).

Example 2

The procedures as described in Example 1 were repeated, except that 585 mg of 4-isopropoxythiobenzamide was used instead of 3-isopropoxythiobenzamide, to give 625 mg of 2-(4-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 75%).

m.p.: 186 - 188°C

¹H-NMR (CDCl₃) δ:

7.89 (d, 2H, J = 9.0 Hz), 6.94 (d, 2H, J = 9.0 Hz), 4.62 (m, 1H), 2.79 (s, 3H), 1.38 (d, 6H, J = 6.2 Hz).

Example 3

730 mg of 3-Nitrothiobenzamide was dissolved in 5 ml of ethanol, 725 mg of ethyl 2-chloroacetoacetate was added to the solution, and the mixture was heated under reflux for 18 hours. After the reaction mixture was cooled, the precipitated crystal was collected by filtration and recrystallized from a mixed solvent consisting of 10 ml of ethanol and 5 ml of ethyl acetate. 800 mg out of 898 mg of the resulting crystal was suspended in 10 ml of ethanol, 10 ml of an aqueous 1 N sodium hydroxide solution was added to the suspension, and the mixture was heated at 70°C for 2 hours. After the completion of the reaction, ethanol was removed by distillation, and the residue was neutralized with 1 N hydrochloric

EP 0 513 379 B1

acid. The precipitated crystal was collected by filtration and recrystallized from an aqueous 50% ethanol solution to give 560 mg of 4-methyl-2-(3-nitrophenyl)-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 235 - 236°C

¹H-NMR (DMSO d-6) δ:

8.68 (dd, 1H), 8.35 (dd, 2H), 7.80 (t, 1H), 2.81 (s, 3H).

Example 4

The procedures as described in Example 3 were repeated, except that 730 mg of 4-nitrothiobenzamide was used instead of 3-nitrothiobenzamide, to give 490 mg of 4-methyl-2-(4-nitrophenyl)-5-thiazolecarboxylic acid (yield: 51%).

m.p.: 252 - 253°C

¹H-NMR (DMSO d-6) δ:

8.32 (d, 2H, J = 9.0 Hz), 8.13 (d, 2H, J = 9.0 Hz), 2.82 (s, 3H).

Compounds described in the following Examples were prepared in the same manner as that described above.

Example 5

4-Methyl-2-(3-trifluoromethylphenyl)-5-thiazolecarboxylic acid (yield: 49%).

m.p.: 171 - 172°C

¹H-NMR (CDCl₃) δ:

7.49 - 8.27 (m, 4H), 2.83 (s, 3H).

Example 6

4-Methyl-2-(4-trifluoromethylphenyl)-5-thiazolecarboxylic acid (yield: 52%).

m.p.: about 220°C (sublimated)

¹H-NMR (CDCl₃) δ:

8.13 (d, 2H, J = 8.1 Hz), 7.71 (d, 2H, J = 8.1 Hz), 2.80 (s, 3H).

Example 7

2-(4-Cyclohexylmethoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 88%).

m.p.: 193 - 195°C

¹H-NMR (CDCl₃) δ:

7.89 (d, 2H, J = 8.8 Hz), 6.90 (d, 2H, J = 8.8 Hz), 4.01 (d, 2H, J = 6.2 Hz), 2.76 (s, 3H), 0.75 - 2.05 (m, 11H).

Example 8

2-(4-(3-Cyclohexylpropyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 83%).

m.p.: 168 - 169°C

¹H-NMR (CDCl₃) δ:

7.91 (d, 2H, J = 8.8 Hz), 6.93 (d, 2H, J = 8.8 Hz), 3.99 (d, 2H, J = 6.3 Hz), 2.78 (s, 3H), 0.70 - 2.00 (m, 15H).

Example 9

2-(4-(4-Chlorobenzyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 79%).

m.p.: 245 - 246°C

¹H-NMR (DMSO d-6) δ:

7.91 (d, 2H, J = 8.8 Hz), 7.46 (s, 4H), 7.12 (d, 2H, J = 8.8 Hz), 5.19 (s, 2H), 2.65 (s, 3H).

Example 10

2-(4-(4-Fluorobenzyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 81%).

m.p.: 251 - 252°C

¹H-NMR (DMSO d-6) δ:

7.92 (d, 2H, J = 8.8 Hz), 7.05 - 7.65 (m, 6H, J = 8.8 Hz), 5.17 (s, 2H), 2.66 (s, 3H).

Example 11

2-(4-Carboxymethyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 79%).

m.p.: 245 - 246°C

Example 12

2-(4-(4-Carboxybutyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 82%).

m.p.: 219 - 220°C

¹H-NMR (DMSO d-6) δ:

7.89 (d, 2H, J = 8.8 Hz), 7.03 (d, 2H, J = 8.8 Hz), 4.05 (t, 2H, J = 5.1 Hz), 2.66 (s, 3H), 2.30 (t, 2H, J = 6.5 Hz), 1.55-1.90 (m, 6H)

Example 13

720 mg of 3-Thiocarbamoylbenzoic acid was suspended in 10 ml of dioxane, 720 mg of ethyl 2-chloroacetoacetate was added thereto, and the mixture was heated at 90°C for 18 hours. After the reaction mixture was cooled, the resulting crystal was collected from the suspension by filtration and recrystallized from 20 ml of ethanol and a small amount of water to give 735 mg of ethyl 2-(3-carboxyphenyl)-4-methyl-5-thiazolecarboxylate (yield: 63%). 290 mg of the crystal was dissolved in 5 ml of 1 N sodium hydroxide, and the mixture was heated at 60°C for one hour. After the completion of the reaction, the reaction mixture was neutralized with 1 N hydrochloric acid. The resulting crystal was collected by filtration and recrystallized from a 80% aqueous ethanol solution to give 258 mg of 2-(3-carboxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 83%).

m.p.: 295 - 296°C

¹H-NMR (DMSO d-6) δ:

8.58 (s, 1H), 8.05 - 8.30 (m, 2H), 7.51 (t, 1H), 2.71 (s, 3H).

Example 14

2-(4-Carboxyphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from 4-thiocarbamoylbenzoic acid through an ethyl 2-(4-carboxyphenyl)-4-methyl-5-thiazolecarboxylate in the same manner as that of Example 13 (yield: 49%).

m.p.: > 300°C

¹H-NMR (DMSO d-6) δ:

8.07 (s, 3H), 2.70 (s, 3H).

Example 15

290 mg of Ethyl 2-(3-carboxyphenyl)-4-methyl-5-thiazolecarboxylate was suspended in 2 ml of benzene, 2 ml of thionyl chloride was added to the suspension, and the mixture was heated at 80°C for 3 hours. The reaction mixture was concentrated, and the residue was dissolved in 1,2-dichloroethane. To the solution was added a solution (5 ml) of 250 mg of p-chloroaniline in 1,2-dichloroethane, and 200 mg of triethylamine was added thereto. The mixture was heated at 80°C for 30 minutes and cooled, and 15 ml of 1 N hydrochloric acid was added thereto. The mixture was extracted twice with 30 ml of ethyl acetate. The organic layer was washed with an aqueous sodium bicarbonate solution and an aqueous saturated sodium chloride solution and evaporated to dryness, and the resulting crystal was recrystallized from a 80% aqueous ethanol solution to give 212 mg of ethyl 2-(3-(4-chlorophenylcarbamoyl)phenyl)-4-methyl-5-thiazolecarboxylate. This product was suspended in 3 ml of ethanol, hydrolyzed with 2 ml of a 1N aqueous sodium

EP 0 513 379 B1

hydroxide solution and neutralized. The resulting crystal was recrystallized from aqueous ethanol solution to give 162 mg of 2-(3-(4-chlorophenylcarbamoyl)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 43%).

m.p.: 246 - 248°C

Example 16

175 mg of 2-(4-(4-chlorophenylcarbamoyl)phenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from 290 mg of ethyl 2-(4-carboxyphenyl)-4-methyl-5-thiazolecarboxylate in the same manner as that of Example 15 (yield: 47%).

m.p.: 276 - 278°C

¹H-NMR (DMSO d-6) δ:

10.47 (s, 1H), 8.10 (s, 4H), 7.83 (d, 2H, J = 8.8 Hz), 7.40 (d, 2H, J = 8.8 Hz), 2.71 (s, 3H).

Example 17

100 mg of Ethyl 2-(4-(4-chlorophenylcarbamoyl)phenyl)-4-methyl-5-thiazolecarboxylate produced in Example 16 was methylated with sodium hydride and methyl iodide, and hydrolyzed by a conventional process to give 69 mg of 2-(4-(N-(4-chlorophenyl)-N-methylcarbamoyl)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 72%).

m.p.: 210 - 212°C

¹H-NMR (CDCl₃ + CD₃ OD) δ:

7.78 (d, 2H, J = 8.6 Hz), 7.37 (d, 2H, J = 8.6 Hz), 7.21 (d, 2H, J = 9.0 Hz), 7.02 (d, 2H, J = 9.0 Hz), 3.48 (s, 3H), 2.74 (s, 3H).

Example 18

2-(4-(N,N-dimethylamino)phenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from 4-(N,N-dimethylamino)thiobenzamide in the same manner as that of Example 1 (yield: 68%).

m.p.: 226 - 231°C

¹H-NMR (DMSO d-6) δ:

7.77 (d, 2H, J = 8.9 Hz), 6.76 (d, 2H, J = 8.9 Hz), 3.00 (s, 6H), 2.62 (s, 3H).

Example 19

2-(3-Benzoylphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from 3-benzoylthiobenzamide in the same manner as that of Example 1 (yield: 57%).

m.p.: 213 - 215°C

¹H-NMR (DMSO d-6) δ:

8.05 - 8.35 (m, 2H), 7.35 - 8.00 (m, 7H), 2.71 (s, 3H).

Example 20

2-(4-Benzoylphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from 4-benzoylthiobenzamide in the same manner as that of Example 1 (yield: 48%).

m.p.: 217 - 218°C

¹H-NMR (DMSO d-6) δ:

8.15 (d, 2H, J = 8.4 Hz), 7.85 (d, 2H, J = 8.4 Hz), 7.45 - 7.90 (m, 5H), 2.71 (s, 3H).

Example 21

340 mg of 3-Chlorothiobenzamide was dissolved in 10 ml of ethanol, 570 mg of diethyl bromomalonate was added to the solution, and the mixture was heated at 60°C for 2 hours. After the reaction mixture was cooled, and the resulting crystal was collected by filtration and recrystallized from ethanol to give 408 mg of ethyl 2-(3-chlorophenyl)-4-hydroxy-5-thiazolecarboxylate. This product was hydrolyzed by a conventional process to give 306 mg of 2-(3-chlorophenyl)-4-hydroxy-5-thiazolecarboxylic acid (yield: 60%).

EP 0 513 379 B1

m.p.: 107 - 108°C

¹H-NMR (DMSO d-6) δ:

7.65 - 8.00 (m, 2H), 7.30 - 7.45 (m, 2H).

5 Example 22

290 mg of 4-Hydroxy-2-(4-isopropoxyphenyl)-5-thiazolecarboxylic acid was prepared from 390 mg of 4-isopropoxythiobenzamide in the same manner as that of Example 21 (yield: 52%).

10 m.p.: 126 - 127°C

¹H-NMR (DMSO d-6) δ:

7.99 (d, 2H, J = 9.0 Hz), 7.00 (d, 2H, J = 9.0 Hz), 4.72 (m, 1H, J = 5.9 Hz), 1.42 (d, 6H, J = 5.9 Hz).

Example 23

15

Ethyl 4-hydroxy-2-(4-isopropoxyphenyl)-5-thiazolecarboxylate prepared in Example 22 was methylated with sodium hydride and methyl iodide and hydrolyzed by a conventional process to give 2-(4-isopropoxyphenyl)-4-methoxy-5-thiazolecarboxylic acid (yield: 72%).

20 m.p.: 109 - 110°C

¹H-NMR (DMSO d-6) δ:

7.90 (d, 2H, J = 9.0 Hz), 6.91 (d, 2H, J = 9.0 Hz), 4.68 (m, 1H, J = 5.9 Hz), 4.23 (s, 3H), 4.23 (s, 3H), 1.39 (d, 6H, J = 5.9 Hz).

25 The following compounds were prepared from corresponding thiobenzamides in the same manner as that of Examples 1 to 4.

Example 24

30 2-(2-Chloro-5-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 66%).

m.p.: 280 - 285°C

¹H-NMR (DMSO d-6) δ:

9.21 (d, 1H, J = 2.7 Hz), 8.11 (dd, 1H, J = 8.9 Hz, J = 2.7 Hz), 7.59 (d, 1H, J = 8.9 Hz), 2.84 (s, 3H).

35

Example 25

2-(3-Acetyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 38%).

40 m.p.: 251 - 253°C

¹H-NMR (DMSO d-6) δ:

8.36 (d, 1H, J = 2.2 Hz), 8.00 (dd, 1H, J = 8.7 Hz, J = 2.2 Hz), 6.96 (d, 1H, J = 8.7 Hz), 2.74 (s, 3H), 3.69 (s, 3H).

Example 26

45

2-(3,5-Bistrifluoromethylphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 72%).

m.p.: 200°C (sublimated)

¹H-NMR (CDCl₃) δ:

50 8.42 (s, 2H), 7.97 (s, 1H), 2.85 (s, 3H).

Example 27

2-(3,5-Dichlorophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 77%).

55

m.p.: 270°C (sublimated)

¹H-NMR (CDCl₃) δ:

8.11 (s, 2H), 7.68 (s, 1H), 2.81 (s, 3H).

Example 28

2-(3,5-Dichloro-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 64%).

m.p.: 260°C (sublimated)

¹H-NMR (CDCl₃) δ:

7.81 (s, 2H), 2.71 (s, 3H).

Example 29

2-(3,5-Di-*t*-butyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 261 - 262°C

¹H-NMR (CDCl₃) δ:

7.80 (s, 2H), 5.58 (s, 1H), 2.79 (s, 3H), 1.49 (s, 18H).

Example 30

2-(3,5-Dimethyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 256 - 257°C

¹H-NMR (CDCl₃) δ:

7.62 (s, 2H), 2.77 (s, 3H), 2.30 (s, 6H).

Example 31

(1) A mixture of 5.0 g of 4-hydroxy-3-nitrobenzaldehyde with 2.5 g of hydroxylamine hydrochloride and 3.6 g of sodium formate was heated under reflux in 35 ml of formic acid for 5 hours. After the reaction mixture was cooled, water was added thereto. The precipitated crystal was collected by filtration to give 4.3 g of 4-hydroxy-3-nitrobenzonitrile. 3.5 g of thioacetamide was added thereto and the mixture was heated at 80°C for 1 hour in 12 ml of N,N-dimethylformamide saturated with hydrochloric acid. After the completion of the reaction, the reaction mixture was neutralized with 30 ml of water and 18 ml of 2 N sodium hydroxide. The precipitated crystal was collected by filtration and recrystallized from ethanol to give 3.9 g of 4-hydroxy-3-nitrobenzthioamide. This product was dissolved in 30 ml of ethanol, 2.7 g of ethyl 2-chloroacetoacetate was added thereto, and the mixture was heated under reflux for 5 hours. The reaction mixture was cooled, and the precipitated crystal was collected by filtration and recrystallized from ethanol to give 3.4 g of ethyl 2-(4-hydroxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 37%).

(2) 200 mg of Ethyl 2-(4-hydroxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate prepared in (1) was dissolved in 3 ml of N,N-dimethylformamide, 540 mg of anhydrous potassium carbonate and 440 mg of isopropyl bromide were added thereto, and the mixture was heated at 70°C for 18 hours. After the reaction mixture was cooled, 20 ml of water was added thereto. The mixture was extracted twice with 30 ml of ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, and the solvent was removed by distillation. The resulting crystal was recrystallized from ethanol to give 172 mg of ethyl 2-(4-isopropoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate. This product was hydrolyzed by a conventional process, and the resulting crystal was recrystallized from a 80% aqueous ethanol solution to give 135 mg of 2-(4-isopropoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 65%).

m.p.: 211 - 213°C

¹H-NMR (DMSO d-6) δ:

8.37 (d, 1H, J = 2.2 Hz), 8.16 (dd, 1H, J = 9.2 Hz, J = 2.2 Hz), 7.49 (d, 1H, J = 9.2 Hz), 4.93 (m, 1H, J = 6.1 Hz), 2.67 (s, 3H), 1.32 (d, 6H, J = 6.1 Hz).

The following compounds were produced in the same manner as that described above.

Example 32

2-(4-Cyclohexylmethoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 228 - 230°C

¹H-NMR (DMSO d-6) δ:

8.45 (d, 1H, J = 2.3 Hz), 8.10 (dd, 1H, J = 8.9 Hz, J = 2.3 Hz), 7.12 (d, 1H, J = 8.9 Hz), 3.96 (d, 2H, J = 5.7 Hz), 2.79 (s, 3H), 0.90 - 2.15 (m, 11H).

5 Example 33

2-(4-Ethoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 234 - 236°C

10 ¹H-NMR (DMSO d-6) δ:

8.39 (d, 1H, J = 2.2 Hz), 8.17 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.46 (d, 1H, J = 8.8 Hz), 4.31 (q, 2H, J = 7.0 Hz), 2.67 (s, 3H), 1.38 (t, 3H, J = 7.0 Hz).

Example 34

15

2-(4-Isobutyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 42%).

m.p.: 210 - 212°C

¹H-NMR (CDCl₃) δ:

20 8.45 (d, 1H, J = 2.2 Hz), 8.11 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.13 (d, 1H, J = 8.8 Hz), 3.94 (d, 2H, J = 6.8 Hz), 2.80 (s, 3H), 2.00 - 2.35 (m, 1H), 1.17 (d, 6H, J = 6.8 Hz).

Example 35

25

2.9 g of Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was prepared from 3.4 g of 4-chloro-3-nitrobenzaldehyde in the same manner as that of Example 31 (yield: 48%). 330 mg of this product was weighed and dissolved in 5 ml of ethanol, 200 mg of anhydrous potassium carbonate and 80 mg of 2-mercaptopropane were added thereto, and the mixture was heated at 80°C for 2 hours. After the completion of the reaction, ethanol was removed by distillation, 20 ml of water was added thereto, and the mixture was extracted twice with 30 ml of ethyl acetate. After the organic layer was washed with an aqueous saturated sodium chloride solution, the solvent was removed by distillation. The resulting crystal was recrystallized from ethanol to give 213 mg of ethyl 2-(4-isopropylthio-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate. This product was hydrolyzed by a conventional process, and the resulting crystal was recrystallized from ethanol to give 162 mg of 2-(4-isopropylthio-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 48%).

35

m.p.: 233 - 235°C

¹H-NMR (DMSO d-6) δ:

8.64 (d, 1H, J = 2.1 Hz), 8.03 (dd, 1H, J = 8.5 Hz, J = 2.1 Hz), 7.44 (d, 1H, J = 8.5 Hz), 3.59 (m, 1H, J = 6.6 Hz), 2.74 (s, 3H), 1.39 (d, 6H, J = 6.6 Hz).

40 Example 36

Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was reacted with 4-chlorothiophenol in the same manner as that of Example 35 to give 2-(4-(4-chlorophenyl)thio-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 65%).

45

m.p.: 250°C (sublimated)

¹H-NMR (DMSO d-6) δ:

8.74 (d, 1H, J = 2.0 Hz), 8.08 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz), 7.66 (s, 4H), 7.00 (d, 1H, J = 8.8 Hz), 2.68 (s, 3H).

50 Example 37

Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate in diethylamine was heated in the same manner as that of Example 35 and hydrolyzed to give 2-(4-N,N-diethylamino-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 56%).

55

m.p.: 208 - 210°C

¹H-NMR (DMSO d-6) δ:

8.24 (d, 1H, J = 2.2 Hz), 7.84 (dd, 1H, J = 8.9 Hz, J = 2.2 Hz), 7.02 (d, 1H, J = 8.9 Hz), 3.21 (q, 4H), 2.66 (s, 3H), 1.10 (t, 6H).

Example 38

Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate in pyrrolidine was heated in the same manner as that of Example 37 and hydrolyzed to give 2-(4-morpholino-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 57%).

m.p.: 218 - 220°C

¹H-NMR (DMSO d-6) δ:

8.26 (d, 1H, J = 2.2 Hz), 7.95 (dd, 1H, J = 9.0 Hz, J = 2.2 Hz), 7.12 (d, 1H, J = 9.0 Hz), 3.05 - 3.45 (m, 4H), 2.65 (s, 3H), 1.70 - 2.30 (m, 4H).

Compounds of Examples 39 to 42 were prepared in the same manner as that of Example 31.

Example 39

2-(4-(2-Ethoxyethoxy)-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 73%).

m.p.: 197 - 199°C (decomposed)

¹H-NMR (DMSO d-6) δ:

8.45 (d, 1H, J = 2.4 Hz), 8.10 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz), 7.20 (d, 1H, J = 8.8 Hz), 4.35 (t, 2H, J = 4.8 Hz), 3.86 (t, 2H, J = 4.8 Hz), 3.63 (q, 2H, J = 7.0 Hz), 2.79 (s, 3H), 1.23 (t, 3H, J = 7.0 Hz).

Example 40

2-(4-Isopentyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 68%).

m.p.: 217 - 219°C

¹H-NMR (CDCl₃) δ:

8.41 (d, 1H, J = 2.2 Hz), 8.09 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.13 (d, 1H, J = 8.8 Hz), 4.20 (t, 2H, J = 6.4 Hz), 2.77 (s, 3H), 1.6 - 2.0 (m, 3H), 0.98 (d, 6H, J = 5.9 Hz).

Example 41

2-(4-n-Hexyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 62%).

m.p.: 194 - 195°C

¹H-NMR (DMSO-d₆) δ:

8.41 (d, 1H, J = 2.2 Hz), 8.19 (dd, 1H, J = 9.0 Hz, J = 2.2 Hz), 7.47 (d, 1H, J = 9.0 Hz), 4.24 (t, 2H, J = 6.2 Hz), 2.67 (s, 3H), 0.75 - 1.97 (m, 11H).

Example 42

2-(4-(2-Ethylbutyloxy)-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 230 - 231°C

¹H-NMR (DMSO-d₆) δ:

8.41 (d, 1H, J = 2.0 Hz), 8.19 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz), 7.50 (d, 1H, J = 8.8 Hz), 4.15 (d, 2H, J = 5.7 Hz), 2.68 (s, 3H), 1.1 - 1.9 (m, 5H), 0.91 (t, 6H, J = 6.6 Hz).

Example 43

1.83 g of 4-Chloro-3-nitrobenzonitrile and 1.06 g of neopentyl alcohol were dissolved in 10 ml of N,N-dimethylformamide. The solution was cooled to 0°C, and 480 mg of sodium hydride (60% in oil) was gradually added thereto. Then, 30 min after the addition, 13 ml of 1 N hydrochloric acid was added to the mixture, and the precipitated crystal was collected by filtration to give 2.12 g of 4-neopentyloxy-3-nitrobenzonitrile. 1.2 g of thioacetamide was added thereto, and the mixture was heated at 80°C for an hour in N,N-dimethylformamide saturated with hydrochloric acid. After the completion of the reaction, the reaction mixture was neutralized with 30 ml of water and 18 ml of 2 N sodium hydroxide, and the lower layer was separated and dried. The lower layer was dissolved in 30 ml of ethanol, 2.11 g of ethyl 2-chloroacetoacetate was added thereto, and the mixture was heated under reflux for 5 hours. After the reaction mixture was

EP 0 513 379 B1

cooled, the precipitated crystal was collected by filtration and recrystallized from ethanol to give 2.38 g of ethyl 4-methyl-2-(4-neopentyloxy-3-nitrophenyl)-5-thiazolecarboxylate (yield: 63%). This product was hydrolyzed by a conventional process, and the resulting crystal was recrystallized from a 80% aqueous ethanol solution to give 1.98 g of 2-(4-neopentyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 90%).

m.p.: 242 - 245°C

¹H-NMR (CDCl₃) δ:

8.47 (d, 1H, J = 2.2 Hz), 8.15 (dd, 1H, J = 8.8 Hz, J = 2.3 Hz), 7.12 (d, 1H, J = 8.8 Hz), 3.80 (s, 2H), 2.80 (s, 3H), 1.09 (s, 9H).

Example 44

As described in Example 37, ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was reacted in piperidine, and the resulting ethyl 4-methyl-2-(3-nitro-4-piperidinophenyl)-5-thiazolecarboxylate was hydrolyzed by a conventional process to give 135 mg of 4-methyl-2-(3-nitro-4-piperidinophenyl)-5-thiazolecarboxylic acid (yield: 63%).

m.p.: 249 - 251°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

8.30 (d, 1H, J = 2.2 Hz), 8.01 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.31 (d, 1H, J = 8.8 Hz), 3.0 - 3.3 (m, 4H), 2.66 (s, 3H), 1.5 - 1.8 (m, 6H).

Example 45

As described in Example 37, ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was reacted in morpholine, and the resulting ethyl 4-methyl-2-(4-morpholino-3-nitrophenyl)-5-thiazolecarboxylate was hydrolyzed by a conventional process to give 4-methyl-2-(4-morpholino-3-nitrophenyl)-5-thiazolecarboxylic acid (yield: 71%).

m.p.: 251 - 252°C

¹H-NMR (DMSO-d₆) δ:

8.35 (d, 1H, J = 2.2 Hz), 8.08 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.36 (d, 1H, J = 8.8 Hz), 3.6 - 3.9 (m, 4H), 3.0 - 3.3 (m, 4H), 2.67 (s, 3H).

Example 46

As described in Example 37, ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was reacted in 1-methylpiperazine, and the resulting ethyl 4-methyl-2-(4-(4-methylpiperazinyl)-3-nitrophenyl)-5-thiazolecarboxylate was hydrolyzed by a conventional process to give 4-methyl-2-(4-(4-methylpiperazinyl)-3-nitrophenyl)-5-thiazolecarboxylic acid (yield: 58%).

m.p.: 218 - 220°C

¹H-NMR (DMSO-d₆) δ:

8.33 (d, 1H, J = 2.2 Hz), 8.05 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.37 (d, 1H, J = 8.8 Hz), 2.9 - 3.4 (m, 4H), 2.66 (s, 3H), 2.3 - 2.7 (m, 4H), 2.29 (s, 3H).

Example 47

200 mg of Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was suspended in 5 ml of isopropyl alcohol, and 60 mg of sodium hydride (60% in oil) was added thereto at room temperature. After 20 hours of the addition, 20 ml of water was added to the mixture, the precipitated crystal was collected by filtration, and recrystallized from ethanol to give 165 mg of isopropyl 2-(4-isopropoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 74%).

m.p.: 91 - 92°C

¹H-NMR (CDCl₃) δ:

8.37 (d, 1H, J = 2.2 Hz), 8.07 (dd, 1H, J = 8.9 Hz, J = 2.2 Hz), 7.15 (d, 1H, J = 8.9 Hz), 5.1 - 5.4 (m, 1H), 4.6 - 4.9 (m, 1H), 2.76 (s, 3H), 1.2 - 1.6 (m, 12H).

Example 48

160 mg of Isobutyl 2-(4-isobutyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was prepared from 200 mg of ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate in the same manner as that of Example 47 (yield: 67%).

m.p.: 112 - 113°C

¹H-NMR (CDCl₃) δ:

8.43 (d, 1H, J = 2.2 Hz), 8.10 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.11 (d, 1H, J = 8.8 Hz), 4.09 (d, 2H, J = 6.6 Hz), 3.93 (d, 2H, J = 6.4 Hz), 2.77 (s, 3H), 1.9 - 2.4 (m, 2H), 0.9 - 2.2 (m, 12H).

Example 49

(1) 5.0 g of Ethyl 2-(4-hydroxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was dissolved in 120 ml of ethanol and 60 ml of ethyl acetate, and 2 ml of concentrated hydrochloride and 500 mg of a 10% palladium/carbon was added thereto, and the mixture was stirred under a hydrogen atmosphere for 24 hours. After the completion of the reaction, methanol and water were added thereto, the mixture was filtered, and the filtrate was concentrated. The resulting crystal was suspended in 25 ml of 2N hydrochloric acid and 25 ml of acetone, and a solution of 1.2 g of sodium nitrite in 8 ml of water was gradually added thereto with ice cooling. Separately, 2.2 g of cuprous chloride was suspended in 15 ml of 2N hydrochloric acid and the diazonium salt solution was gradually added thereto with ice cooling. After the completion of the dropwise addition, the reaction mixture was heated to 60°C, and one hour after the heating, 100 ml of water was added thereto. The precipitated crystal was collected by filtration. This product was purified by silica gel chromatography to give 4.4 g of ethyl 2-(3-chloro-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate (yield: 91%).

(2) 300 mg of the Phenol derivative produced in (1) was suspended in 5 ml of N,N-dimethylformamide, 690 mg of anhydrous potassium carbonate and 550 mg of ethyl bromide were added thereto, and the mixture was stirred at 70°C for 24 hours. After the completion of the reaction, the reaction product was poured into water, and the mixture was extracted with ether. The organic layer was concentrated to give a crystalline product. This product was hydrolyzed by a conventional process and purified by recrystallization to give 230 mg of 2-(3-chloro-4-ethoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 71%).

m.p.: 219 - 220°C

¹H-NMR (DMSO-d₆) δ:

7.96 (d, 1H, J = 2.4 Hz), 7.82 (dd, 1H, J = 8.6 Hz, J = 2.4 Hz), 7.23 (d, 1H, J = 8.6 Hz), 4.20 (q, 2H, J = 7.0 Hz), 2.66 (s, 3H), 1.40 (t, 3H, J = 7.0 Hz).

The following compounds were prepared in the same manner as that described above.

Example 50

2-(3-Chloro-4-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 65%).

m.p.: 199 - 200°C

¹H-NMR (DMSO-d₆) δ:

7.98 (d, 1H, J = 2.2 Hz) 7.68 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz) 7.26 (d, 1H, J = 8.8 Hz) 4.78 (s, 1H, J = 6.2 Hz) 2.66 (s, 3H) 1.34 (d, 6H, J = 6.2 Hz).

Example 51

2-(3-Chloro-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 58%).

m.p.: 182 - 183°C

¹H-NMR (DMSO-d₆) δ:

7.98 (d, 1H, J = 2.0 Hz), 7.87 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz), 7.23 (d, 1H, J = 8.4 Hz), 3.92 (d, 2H, J = 6.4 Hz), 2.66 (s, 3H), 1.9 - 2.3 (m, 1H), 1.03 (d, 6H, J = 6.6 Hz).

Example 52

2-(3-Chloro-4-isopentyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 67%).

EP 0 513 379 B1

m.p.: 165 - 166°C

¹H-NMR (DMSO-d₆) δ:

7.98 (d, 1H, J = 2.0 Hz), 7.88 (dd, 1H, J = 8.6 Hz, J = 2.0 Hz), 7.26 (d, 1H, J = 8.6 Hz), 4.17 (t, 2H, J = 6.4 Hz), 2.66 (s, 3H), 1.5 - 1.9 (m, 3H), 0.96 (d, 6H, J = 5.9 Hz).

Example 53

2-(3-Chloro-4-(2-ethylbutyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 62%).

m.p.: 154 - 156°C

¹H-NMR (DMSO-d₆) δ:

7.97 (d, 1H, J = 2.0 Hz), 7.87 (dd, 1H, J = 8.6 Hz, J = 2.0 Hz), 7.26 (d, 1H, J = 8.6 Hz), 4.04 (d, 2H, J = 5.1 Hz), 2.66 (s, 3H), 1.3 - 1.8 (m, 5H), 0.92 (d, 6H, J = 7.0 Hz).

Example 54

2-(3-Chloro-4-(neopentyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 49%).

m.p.: 218 - 220°C

¹H-NMR (DMSO-d₆) δ:

7.98 (d, 1H, J = 2.2 Hz), 7.87 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz), 7.21 (d, 1H, J = 8.6 Hz), 3.79 (s, 2H), 2.66 (s, 3H), 1.05 (m, 9H).

Example 55

2-(3-Chloro-4-(2-ethoxyethyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 51%).

m.p.: 147 - 148°C

¹H-NMR (DMSO-d₆) δ:

7.99 (d, 1H, J = 2.2 Hz), 7.88 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz), 7.27 (d, 1H, J = 8.6 Hz), 4.2 - 4.4 (m, 2H), 3.7 - 3.9 (m, 2H), 3.55 (q, 2H, J = 6.8 Hz), 2.66 (s, 3H), 1.14 (t, 3H, J = 6.8 Hz).

Example 56

2-(3-Chloro-4-(2-morpholinoethyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 57%).

m.p.: 207 - 209°C

¹H-NMR (DMSO-d₆) δ:

7.98 (d, 1H, J = 2.0 Hz), 7.87 (dd, 1H, J = 8.6 Hz, J = 2.0 Hz), 7.27 (d, 1H, J = 8.6 Hz), 4.27 (t, 2H, J = 5.6 Hz), 3.5 - 3.7 (m, 4H), 2.79 (t, 2H, J = 5.6 Hz), 2.66 (s, 3H), 2.4 - 2.7 (m, 4H).

Example 57

2-(3-Chloro-4-(2-piperidinoethyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 49%).

m.p.: 240 - 243°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

7.94 (d, 1H, J = 2.0 Hz), 7.81 (dd, 1H, J = 8.6 Hz, J = 2.0 Hz), 7.25 (d, 1H, J = 8.6 Hz), 4.32 (t, 2H, J = 5.5 Hz), 2.94 (t, 2H, J = 5.5 Hz), 2.66 (s, 3H), 2.5 - 2.8 (m, 4H), 1.3 - 1.8 (m, 6H).

Example 58

2-(3-Chloro-4-(4-fluorobenzyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 63%).

m.p.: 260 - 265°C (sublimated)

¹H-NMR (DMSO-d₆) δ:

8.01 (d, 1H, J = 2.2 Hz), 7.90 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz), 7.1 - 7.7 (m, 5H), 5.28 (s, 2H), 2.66 (s, 3H).

Example 59

(1) 4.6 g of Ethyl 2-(4-chloro-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was prepared from 5.0 g of 4-chloro-3-nitrobenzaldehyde in the same manner as that of Example 31 (yield: 51%). This product was taken up in 10 ml of morpholine, and stirred for 2 hours, to the mixture was added 30 ml of water, and the precipitated crystal was collected by filtration. The resulting crystal was recrystallized from ethanol to give 1.02 g of ethyl 4-methyl-2-(4-morpholino-3-nitrophenyl)-5-thiazolecarboxylate (yield: 89%).

(2) 1.0 g of Ethyl 4-methyl-2-(4-morpholino-3-nitrophenyl)-5-thiazolecarboxylate thus obtained, was suspended in 80 ml of ethanol, and to the suspension was added 200 mg of 10% palladium/carbon, followed by stirring in a hydrogen atmosphere. After seven hours, the catalyst was removed by filtration, and the filtrate was concentrated to give a crystalline product. The resulting product was suspended in 10 ml of 5N hydrochloric acid and 10 ml of acetone, and to the suspension was gradually added 180 mg of sodium nitrite. Separately, 340 mg of cuprous chloride was suspended in 5 ml of 2N hydrochloric acid, and the diazonium solution was gradually dropwise added thereto with ice cooling. After completion of the dropwise addition, the reaction mixture was heated to 60°C for 30 minutes with stirring, water was added to the reaction mixture, and the precipitated crystal was collected by filtration. This product was purified by silica gel chromatography to give 520 mg of ethyl 2-(3-chloro-4-morpholinophenyl)-4-methyl-5-thiazolecarboxylate. This compound was hydrolyzed by a conventional process. Recrystallisation from acetone-H₂O afforded 240 mg of 2-(3-chloro-4-morpholinophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 27%).

m.p.: 228- 229°C (decomposed)

¹H-NMR (CDCl₃ + CD₃ OD) δ:

7.89 (d, 1H, J = 2.2 Hz), 7.72 (d, 1H, J = 8.4 Hz, J = 2.2 Hz), 7.05 (d, 1H, J = 8.4 Hz), 3.7 - 3.9 (m, 4H), 2.9 - 3.1 (m, 4H), 2.64 (s, 3H).

The following compounds were prepared in the same manner as that described above.

Example 60

2-(3-Chloro-4-piperidinophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 19%).

m.p.: 227 - 230°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

7.94 (d, 1H, J = 2.0 Hz), 7.84 (dd, 1H, J = 8.1 Hz, J = 2.0 Hz), 7.19 (d, 1H, J = 8.1 Hz), 2.9 - 3.2 (m, 4H), 2.66 (s, 3H), 1.5 - 1.8 (m, 6H).

Example 61

2-(3-Chloro-4-(4-chlorophenylthio)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 32%).

m.p.: 238 - 240°C

¹H-NMR (DMSO-d₆) δ:

8.05 (d, 1H, J = 1.8 Hz), 7.80 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.55 (s, 4H), 6.99 (d, 1H, J = 8.4 Hz), 2.66 (s, 3H).

Example 62

350 mg of Ethyl 2-(3-chloro-4-(4-chlorophenylthio)phenyl)-4-methyl-5-thiazolecarboxylate, which was an intermediate in Example 61, was suspended in 5 ml of acetic acid, and 3 ml of 30% aqueous hydrogen peroxide solution was added thereto, followed by stirring for 5 hours. After completion of the reaction, water was added to the reaction mixture, the precipitated crystal was collected by filtration, and the product was purified by silica gel chromatography, and hydrolyzed by a conventional process to give 85 mg of 2-(3-chloro-4-(4'-chlorophenylsulfinyl)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 26%).

m.p.: 257 - 259°C

¹H-NMR (DMSO-d₆) δ:

8.0 - 8.4 (m, 3H), 7.70 (q, 4H, J = 8.8 Hz), 2.68 (s, 3H).

Example 63

(1) 5.0 g of Ethyl 2-(4-hydroxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was dissolved in 120 ml of ethanol and 60 ml of ethyl acetate, 500 mg of a 10% palladium/carbon was added thereto, and the mixture was stirred in a hydrogen atmosphere at room temperature for 24 hours. After the completion of the reaction, chloroform was added thereto, the mixture was filtered, and the filtrate was concentrated. The resulting crystal was suspended in 2 ml of hydrobromic acid, 10 ml of water and 25 ml of acetone, and a solution of 1.2 g of sodium nitrite in 8 ml of water was gradually added thereto with ice cooling. Separately, 2.2 g of cuprous bromide was suspended in 2 ml of hydrobromic acid and 10 ml of water, and the diazonium salt solution was gradually added dropwise thereto with ice cooling. After the completion of the dropwise addition, the reaction mixture was heated to 60°C, and one hour after the heating, 100 ml of water was added thereto. The precipitated crystal was collected by filtration. This product was purified by silica gel chromatography to give 3.6 g of ethyl 2-(3-bromo-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate (yield: 65%).

(2) 340 mg of the phenol derivative prepared in step (1) was suspended in 5 ml of N,N-dimethylformamide, 690 mg of anhydrous potassium carbonate and 690 mg of isobutyl bromide were added thereto, and the mixture was stirred at 70°C for 24 hours. After the completion of the reaction, the reaction product was poured into water, and the mixture was extracted with ether. The organic layer was concentrated to give a crystalline product. This product was hydrolyzed by a conventional process and purified by recrystallisation to give 310 mg of 2-(3-bromo-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 78%).

m.p.: 200 - 202°C

¹H-NMR (DMSO-d₆) δ:

8.18 (d, 1H, J = 2.2 Hz), 7.88 (dd, 1H, J = 8.6 Hz, J = 2.2 Hz), 7.19 (d, 1H, J = 8.6 Hz), 3.89 (d, 2H, J = 6.4 Hz), 2.66 (s, 3H), 2.0 - 2.3 (m, 1H), 1.03 (d, 6H, J = 6.4 Hz).

The following compounds were prepared in the same manner as that described above.

Example 64

2-(3-Bromo-4-(2-ethoxyethoxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 163 - 164°C

¹H-NMR (DMSO-d₆) δ:

8.14 (d, 1H, J = 2.0 Hz), 7.91 (dd, 1H, J = 8.8 Hz, J = 2.2 Hz), 7.23 (d, 1H, J = 8.8 Hz), 4.2 - 4.4 (m, 2H), 3.7 - 3.9 (m, 2H), 3.56 (q, 2H, J = 7.0 Hz), 2.66 (s, 3H), 1.14 (t, 3H, J = 6.8 Hz).

Example 65

2-(3-Bromo-4-(4-chlorophenylthio)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 28%).

m.p.: 232 - 234°C

¹H-NMR (DMSO-d₆) δ:

8.20 (d, 1H, J = 1.8 Hz), 7.83 (dd, 1H, J = 8.4 Hz, J = 1.8 Hz), 7.56 (s, 3H), 6.93 (d, 1H, J = 8.4 Hz), 2.66 (s, 3H).

Example 66

2-(3-Bromo-4-piperidinophenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 29%).

m.p.: 221 - 224°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

8.11 (d, 1H, J = 2.0 Hz), 7.87 (dd, 1H, J = 8.3 Hz, J = 2.0 Hz), 7.17 (d, 1H, J = 8.3 Hz), 2.8 - 3.2 (m, 4H), 2.66 (s, 3H), 1.5 - 1.9 (m, 6H).

Example 67

330 mg of Ethyl 2-(3-amino-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate was dissolved in 15 ml of methylene chloride, 130 mg of nitronium tetrafluoroborate was added thereto with ice cooling, followed by stirring for 4 hours. The reaction mixture was concentrated, irradiated with a UV lamp at 300 nm for 20 hours and purified by silica gel chromatography to give 175 mg of ethyl 2-(3-fluoro-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate. This product was

EP 0 513 379 B1

hydrolyzed by a conventional process and recrystallized from acetone-water to give 108 mg of 2-(3-fluoro-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 35%).

¹H-NMR (DMSO-d₆) δ:

7.6 - 8.0 (m, 2H), 6.8 - 7.0 (m, 1H), 3.83 (d, 2H, J = 6.4 Hz), 2.70 (s, 3H), 2.0 - 2.3 (m, 1H), 1.05 (d, 6H, J = 6.6 Hz).

Example 68

3.2 g of Ethyl 2-(3,5-dichloro-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate was prepared from 3.8 g of 3,5-dichloro-4-hydroxybenzonitrile in the same manner as that of Example 31 (yield: 48%). 330 mg of this product was weighed and suspended in 5 ml of N,N-dimethylformamide, 700 mg of anhydrous potassium carbonate and 620 mg of isopropyl bromide were added thereto, and the mixture was stirred at 70°C for 24 hours. After the completion of the reaction, the reaction mixture was poured into water and extracted with ether. The organic layer was concentrated to give a crystalline product. This product was hydrolyzed by a conventional process and purified by recrystallization to give 250 mg of 2-(3,5-dichloro-4-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 67%).

m.p.: 189 - 191°C

¹H-NMR (DMSO-d₆) δ:

8.03 (s, 2H), 4.66 (q, 1H, J = 6.2 Hz), 2.67 (s, 3H), 1.34 (d, 6H, J = 6.2 Hz).

The following compounds were prepared in the same manner as that described above.

Example 69

2-(3,5-Dichloro-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 54%).

m.p.: 220 - 230°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

8.01 (s, 2H), 3.83 (d, 2H, J = 6.2 Hz), 2.67 (s, 3H), 2.0 - 2.3 (m, 1H), 1.05 (d, 6H, J = 6.6 Hz).

Example 70

2-(3,5-Dichloro-4-(2-ethylbutyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 69%).

m.p.: 189 - 191°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

8.00 (s, 2H), 3.95 (d, 2H, J = 6.2 Hz), 2.67 (s, 3H), 1.3 - 1.7 (m, 5H), 0.95 (t, 6H, J = 6.8 Hz).

Example 71

2-(3,5-Dichloro-4-isopentyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 59%).

m.p.: 193 - 194°C

¹H-NMR (DMSO-d₆) δ:

8.00 (s, 2H), 4.08 (t, 2H, J = 6.6 Hz), 2.67 (s, 3H), 1.5 - 2.0 (m, 3H), 0.95 (d, 6H, J = 6.2 Hz).

Example 72

2-(3,5-Dichloro-4-(2-morpholinoethyloxy)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 58%).

m.p.: 238 - 240°C (decomposed)

¹H-NMR (DMSO-d₆) δ:

8.00 (s, 2H), 4.21 (t, 2H, J = 5.7 Hz), 3.4 - 3.6 (m, 4H), 2.79 (t, 2H, J = 5.7 Hz), 2.67 (s, 3H), 2.4 - 2.6 (m, 4H).

Example 73

(1) 3.46 g of Ethyl 2-(4-carboxyphenyl)-4-methyl-5-thiazolecarboxylate was prepared from 5.0 g of 4-cyanobenzoic acid in the same manner as that of Example 31 (yield: 35%).

EP 0 513 379 B1

(2) 1.0 g of this product was weighed and suspended in 20 ml of benzene, 5 ml of thionyl chloride was added thereto, and a reaction was allowed to react at 80°C for 4 hours. The reaction mixture was evaporated to dryness and again suspended in 30 ml of benzene. 1.15 g of aluminum chloride was added to the suspension, and the mixture was stirred at 60°C for 1 hour. After the completion of the reaction, the reaction product was decomposed with 30 g of ice water and extracted twice with 50 ml of ethyl acetate. The organic layer was washed with an aqueous saturated sodium chloride solution and then concentrated. The resulting crystal was recrystallized from ethanol to give 750 mg of ethyl 2-(4-benzoylphenyl)-4-methyl-5-thiazolecarboxylate. This product was hydrolyzed by a conventional process and recrystallized from ethanol to give 585 mg of 2-(4-benzoylphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 53%).

m.p.: 217 - 218°C

¹H-NMR (DMSO-d₆) δ:

8.15 (d, 2H, J = 8.4 Hz), 7.85 (d, 2H, J = 8.4 Hz), 7.45 - 7.90 (m, 5H), 2.71 (s, 3H).

The following compounds were prepared in the same manner as that described above.

Example 74

4-Methyl-2-(4-(4-methylbenzoyl)phenyl)-5-thiazolecarboxylic acid (yield: 21%).

m.p.: 263 - 265°C

¹H-NMR (CDCl₃) δ:

8.14 (d, 2H, J = 8.6 Hz), 7.82 (d, 2H, J = 8.6 Hz), 7.69 (d, 2H, J = 8.4 Hz), 7.38 (d, 2H, J = 8.4 Hz), 2.71 (s, 3H), 2.43 (s, 3H).

Example 75

2-(4-(2,4-Dimethylbenzoyl)phenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 21%).

m.p.: 184 - 186°C

¹H-NMR (CDCl₃) δ:

8.07 (d, 2H, J = 8.6 Hz), 7.80 (d, 2H, J = 8.6 Hz), 7.0 - 7.4 (m, 3H), 2.72 (s, 3H), 2.32 (s, 3H), 2.20 (s, 3H).

Example 76

1.0 g of Ethyl 2-(4-isopropoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate was dissolved in 20 ml of ethanol and 20 ml of ethyl acetate, 100 mg of a 10% palladium/carbon was added thereto, and the mixture was stirred in a hydrogen atmosphere at room temperature for 24 hours. After completion of the reaction, the catalyst was removed by filtration from the reaction mixture, and the filtrate was concentrated. The resulting crystal was dissolved in 4 ml of concentrated hydrochloric acid, the solution of 215 mg of sodium nitrite in 3 ml of water was gradually added dropwise thereto with ice cooling, and 30 minutes after the dropwise addition, the reaction mixture was neutralized with 40 ml of aqueous saturated sodium bicarbonate solution. Separately, 620 mg of cuprous cyanide and 400 mg of potassium cyanide were suspended in 10 ml of water, the suspension was stirred at 70°C, and then ice cooled, and to the suspension was gradually dropwise added the diazonium salt solution with ice cooling. After the completion of the dropwise addition, the reaction mixture was heated to 60°C for one hour, following by extraction with 100 ml of ethyl acetate. The organic layer was concentrated to give a residue, and the residue was purified by silica gel chromatography to give 400 mg of ethyl 2-(3-cyano-4-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylate (yield: 42%).

This product was dissolved in 3 ml of ethanol and 4 ml of tetrahydrofuran, 2 ml of 1N sodium hydroxide was added thereto, and hydrolysis effected by heating to 60°C for one hour. The solvent was removed by evaporation, the residue was then neutralized by 1N hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was concentrated to dryness, and the resulting solid was recrystallized from ethanol to give 295 mg of 2-(3-cyano-4-isopropoxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 80%).

m.p.: 220 - 222°C

¹H-NMR (DMSO d-6) δ:

8.24 (d, 1H, J = 2.6 Hz), 8.19 (dd, 1H, J = 9.0 Hz, J = 2.6 Hz), 7.38 (d, 1H, J = 9.0 Hz), 4.89 (m, 1H), 2.67 (s, 3H), 1.38 (d, 6H, J = 5.9 Hz).

The following compounds were prepared in the same manner as that described above.

Example 77

2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 2-(4-isobutyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 33%).

m.p.: 238 - 239°C (decomposed)

¹H-NMR (CDCl₃) δ:

8.21 (d, 1H, J = 2.3 Hz), 8.11 (dd, 1H, J = 8.9 Hz, J = 2.3 Hz), 7.03 (d, 1H, J = 8.9 Hz), 3.91 (d, 2H, J = 6.6 Hz), 2.80 (s, 3H), 2.21 (m, 1H), 1.10 (d, 6H, J = 6.6 Hz).

Example 78

2-(3-Cyano-4-neopentyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 2-(4-neopentyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 39%).

m.p.: 221 - 236°C

¹H-NMR (CDCl₃) δ:

8.21 (d, 1H, J = 2.3 Hz), 8.11 (dd, 1H, J = 9.0 Hz, J = 2.3 Hz), 7.02 (d, 1H, J = 9.0 Hz), 3.77 (s, 2H), 2.80 (s, 3H), 1.11 (s, 9H).

Example 79

2-(3-Cyano-4-isopentyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 2-(4-isopentyloxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 29%).

m.p.: 232 - 234°C

¹H-NMR (DMSO d-6) δ:

8.25 (d, 1H, J = 2.0 Hz), 8.20 (dd, 1H, J = 8.9 Hz, J = 2.0 Hz), 7.37 (d, 1H, J = 8.9 Hz), 4.25 (t, 2H, J = 6.5 Hz), 2.67 (s, 3H), 1.6 - 1.9 (m, 3H), 0.98 (d, 6H, J = 6.6 Hz).

Example 80

2-(3-Cyano-4-(2-ethoxyethoxy)phenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 2-(4-ethoxyethoxy-3-nitrophenyl)-4-methyl-5-thiazolecarboxylate (yield: 23%).

m.p.: 206 - 207°C

¹H-NMR (DMSO d-6) δ:

8.25 (d, 1H, J = 2.0 Hz), 8.20 (dd, 1H, J = 8.9 Hz, J = 2.0 Hz), 7.38 (d, 1H, J = 8.9 Hz), 4.36 (m, 2H), 3.78 (m, 2H), 3.56 (q, 2H, J = 6.9 Hz), 2.67 (s, 3H), 1.15 (t, 3H, J = 6.9 Hz).

Example 81

2-(3-Cyano-4-morpholinophenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 4-methyl-2-(4-morpholino-3-nitrophenyl)-5-thiazolecarboxylate (yield: 22%).

m.p.: 252 - 255°C

¹H-NMR (DMSO d-6) δ:

8.12 (d, 1H, J = 2.0 Hz), 8.02 (dd, 1H, J = 8.9 Hz, J = 2.0 Hz), 6.96 (d, 1H, J = 8.9 Hz), 3.84 (m, 4H), 3.27 (m, 4H), 2.70 (s, 3H).

Example 82

2-(3-Cyano-4-piperidinophenyl)-4-methyl-5-thiazolecarboxylic acid was prepared from ethyl 4-methyl-2-(3-nitro-4-piperidinophenyl)-5-thiazolecarboxylate (yield: 28%).

m.p.: 230 - 232°C

¹H-NMR (CDCl₃) δ:

8.17 (d, 1H, J = 2.3 Hz), 8.03 (dd, 1H, J = 8.9 Hz, J = 2.3 Hz), 7.03 (d, 1H, J = 8.9 Hz), 3.29 (m, 4H), 2.73 (s, 3H), 1.5 - 1.8 (m, 6H).

Example 83

100 mg of Ethyl 2-(3-bromo-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate, 95 mg of cuprous iodide and 140 mg of sodium trifluoroacetate were suspended in 2 ml of N-methylpyrrolidone, and the mixture was heated in a nitrogen atmosphere at 140°C for 4 hours. After completion of the reaction, the product was extracted with ethyl acetate, and the organic layer was concentrated to give a crude crystal. The resulting crystal was purified by silica gel chromatography to give 80 mg of ethyl 2-(4-isobutyloxy-3-trifluoromethylphenyl)-4-methyl-5-thiazolecarboxylate. The product was hydrolyzed by a conventional process, following by recrystallization from hexane-ether to give 50 mg of 2-(4-isobutyloxy-3-trifluoromethylphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 56%).

m.p.: 208 - 211°C

¹H-NMR (CDCl₃) δ:

8.21 (d, 1H, J = 2.3 Hz), 8.09 (dd, 1H, J = 8.7 Hz, J = 2.3 Hz), 7.03 (d, 1H, J = 8.9 Hz), 3.89 (d, 2H, J = 6.0 Hz), 2.80 (s, 3H), 2.1 - 2.3 (m, 1H), 1.07 (d, 6H, J = 6.6 Hz).

Example 84

4-Methyl-2-(4-neopentyloxy-3-trifluoromethylphenyl)-5-thiazolecarboxylic acid was prepared from ethyl 2-(3-bromo-4-neopentyloxyphenyl)-4-methyl-5-thiazolecarboxylate in the same manner as that described in Example 83 (yield: 48%).

m.p.: 203 - 204°C

¹H-NMR (DMSO d-6) δ:

8.15 (m, 2H) 7.33 (d, 1H, J = 8.9 Hz), 3.84 (s, 2H), 2.67 (s, 3H), 1.04 (s, 9H).

Example 85

120 mg of Ethyl 2-(3-bromo-4-neopentyloxyphenyl)-4-methyl-5-thiazolecarboxylate, 100 mg of cuprous iodide and 80 mg of lithium iodide were suspended in 2 ml of N-methyl pyrrolidone, and the suspension was heated at 150°C for 4 hours with stirring. After completion of the reaction, the product was extracted with ethyl acetate, and the organic layer was concentrated to give a crude crystal. The resulting crystal was purified by silica gel chromatography to give 95 mg of ethyl 2-(3-iodo-4-neopentyloxyphenyl)-4-methyl-5-thiazolecarboxylate. The product was hydrolyzed by a conventional process, followed by recrystallization from hexane-ether to give 63 mg of 2-(3-iodo-4-neopentyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 58%).

m.p.: 194 - 195°C

¹H-NMR (DMSO d-6) δ:

8.42 (d, 1H, J = 2.0 Hz), 7.90 (d, 1H, J = 8.9 Hz, J = 2.0 Hz), 6.80 (d, 1H, J = 8.9 Hz), 3.71 (s, 2H), 2.79 (s, 3H), 1.12 (s, 9H).

Example 86

150 mg of Ethyl 2-(4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate were dissolved in 2 ml of dichloromethane and 1.8 ml of titanium tetrachloride (1N in dichloromethane) was added thereto with cooling. Then 15 minutes after the addition, to the solution was dropwise added 0.8 ml of α,α-dichloromethyl ether, and the mixture then stirred at 0°C for one hour, and further, allowed to react at 40°C for 24 hours. The reaction mixture was poured into ice-water, and extracted with ethyl acetate, the organic layer was concentrated, and the resulting residue was purified by silica gel chromatography to give 60 mg of ethyl 2-(3-α,α-dichloromethyl)-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylate. This product was hydrolyzed by a conventional process, followed by recrystallization from hexane ether to give 45 mg of 2-(3-formyl-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid (yield: 22%).


m.p.: 213 - 217°C

¹H-NMR (CDCl₃) δ:


10.53 (s, 1H), 8.50 (br.s, 1H), 8.36 (s, 1H), 7.07 (br.s, 1H), 3.95 (d, 2H, J = 5.6 Hz), 2.86 (s, 3H), 2.1 - 2.2 (m, 1H), 1.02 (d, 6H, J = 6.6 Hz).

Examples 87 - 110





According to the process as described above, the following compounds were prepared:





Example No.	Ar	X	Y	Yield (%)	¹ H-NMR (δ in DMSO-d ₆) and m.p.
87	2-pyridyl	CO ₂ H	CH ₃	34	δ: [8.67-8.59(m, 1H), 8.17-8.07(m, 1H), 7.94(dt, 1H, J=1.8, 7.3Hz), 7.54-7.39(m, 1H), 2.70(s, 3H) in DMSO-d ₆] mp: 200-202°C
89	4-pyridyl	CO ₂ H	CH ₃	65	δ: [8.73(m, 2H), 7.89(m, 2H), 2.71(s, 3H)] mp: 200°C (sublimed) in DMSO-d ₆



Example No.	R ₁	R ₂	X	Y	Yield (%)	¹ H-NMR (δ in CDCl ₃ or DMSO-d ₆) and m.p.
90	4-F	H	CO ₂ H	CH ₃	67	δ: [8.1-7.9(m, 2H), 7.33(t, 2H, J=8.8Hz), 2.68(s, 3H) in CDCl ₃]
91	4-O-C ₆ H ₄ -F	H	CO ₂ H	CH ₃	20	δ: [7.91(d, 2H, J=9.0Hz), 7.09-7.01(m, 4H), 6.98(d, 2H, J=9.0Hz), 2.76(s, 3H) in CDCl ₃]
92	3-Cl	4-SO ₂ -C ₆ H ₄ -Cl	CO ₂ H	CH ₃	42	δ: [8.39(d, 1H, J=2.8Hz), 8.13-7.52(m, 6H), 2.68(s, 3H) in CDCl ₃] mp: 214-216°C
93	4-S-C ₆ H ₄ -Cl	H	CO ₂ H	CH ₃	14	δ: [7.9-7.2(m, 4H), 7.26(s, 4H), 4.15(s, 2H), 2.74(s, 3H) in CDCl ₃]
94	3-NO ₂	4-NHCO-C ₆ H ₃ (Cl) ₂	CO ₂ H	CH ₃	62	δ: [11.08(s, 1H), 8.52(d, 1H, J=1.6Hz), 8.32(dd, 1H, J=2.2, 8.6Hz), 7.90(dd, 1H, J=1.6, 8.6Hz), 7.78-7.63(m, 3H), 2.71(s, 3H)] mp: 290-291°C

Example No.	R ₁	R ₂	X	Y	Yield (%)	¹ H-NMR (δ in CDCl ₃ or DMSO-d ₆) and m.p.
95	3-NO ₂		CO ₂ H	CH ₃	70	δ : [13.3 (br. s, 1H), 11.90 (s, 1H), 8.94 (d, 1H, J=8.9Hz), 8.62 (d, 1H, J=2.3Hz), 8.17 (dd, 1H, J=2.3, 8.9Hz), 8.01 (d, 1H, J=9.6Hz), 6.70 (m, 2H), 4.07 (s, 3H), 3.85 (s, 3H), 2.66 (s, 3H)] mp: 285-286°C (decomposed)
96		H	CO ₂ H	CH ₃	23	δ : [8.16 (d, 2H, J=8.6Hz), 8.12 (m, 1H), 7.94 (d, 2H, J=8.6Hz), 7.90 (m, 1H), 7.30 (m, 1H), 2.71 (s, 3H) in DMSO-d ₆]
97		H	CO ₂ H	CH ₃	5	δ : [8.09 (d, 2H, J=8.0Hz), 7.85 (d, 2H, J=8.3Hz), 7.76 (d, 2H, J=8.7Hz), 7.49 (d, 2H, J=8.3Hz), 2.71 (s, 3H) in CDCl ₃]
98		H	CO ₂ H	CH ₃	19	δ : [8.09 (d, 2H, J=8.0Hz), 7.86 (d, 2H, J=7.9Hz), 7.85 (d, 2H, J=8.0Hz), 7.19 (dd, 2H, J=8.2, 8.7Hz), 3.0-3.7 (br. s, 1H) in CDCl ₃]
99	3-CO ₂ Et	H	CO ₂ Et	CH ₃	59	δ : [8.57 (m, 1H), 8.21-8.08 (m, 2H), 7.52 (t, 1H, J=7.7Hz), 4.43 (q, 2H, J=7.0Hz), 4.37 (q, 2H, J=7.0Hz), 2.79 (s, 3H), 1.43 (t, 3H, J=7.0Hz), 1.40 (t, 3H, J=7.0Hz)] in CDCl ₃ mp: 70-71°C

Example No.	R ₁	R ₂	X	Y	Yield (%)	¹ H-NMR(δ in CDCl ₃ or DMSO-d ₆) and m.p.
100	4-CO ₂ Et	H	CO ₂ Et	CH ₃	67	δ: [8.18-7.95(m, 4H), 4.40(q, 2H, J=7.0Hz), 4.37(q, 2H, J=7.0Hz), 2.79(s, 3H), 1.42(t, 3H, J=7.0Hz)] in CDCl ₃ mp: 88-89°C
101	4-CONH	H	CO ₂ H	CH ₃	31	δ: [8.34-8.25(m, 1H), 7.99(m, 4H), 4.14(m, 1H), 2.70(s, 3H), 1.19(d, 6H, J=6.6Hz)] in DMSO-d ₆ mp: 225-226°C (decomposed)
102	4-CONH	H	CO ₂ H	CH ₃	35	δ: [9.90(s, 1H), 8.10(s, 4H), 7.26-7.07(m, 3H), 2.71(s, 3H), 2.30(s, 3H), 2.21(s, 3H)] in DMSO-d ₆ mp: 248-249°C (decomposed)
103	4-CONH	H	CO ₂ H	CH ₃	36	δ: [9.49(s, 1H), 8.08(s, 4H), 7.53(d, 1H, J=8.6Hz), 6.68-6.51(m, 2H), 3.82(s, 3H), 3.79(s, 3H), 2.71(s, 3H)] in DMSO-d ₆ mp: 234-235°C (decomposed)
104	4-CONH	H	CO ₂ H	CH ₃	11	δ: [8.42-8.36(m, 1H), 8.27-8.05(m, 5H), 7.95-7.75(m, 1H), 7.27-7.12(m, 1H), 2.71(s, 3H)] in DMSO-d ₆ mp: 285-287°C (decomposed)

Example No.	R ₁	R ₂	X	Y	Yield (%)	¹ H-NMR(δ in CDCl ₃ or DMSO-d ₆) and m.p.
105	3-CF ₃	H	CO ₂ Et	CH ₃	51	δ: [8.24-8.07(m, 2H), 7.77-7.56(m, 2H), 4.37(q, 2H, J=7.0Hz), 1.40(t, 3H, J=7.0Hz)] in DMSO-d ₆ mp: 87-88°C
106	4-CO- 	H	CONH ₂	CH ₃	37	δ: [7.6-8.2(m, 1H), 2.66(s, 3H) in CDCl ₃]
107	4-CF ₃	H	H	CO ₂ H	42	δ: [8.21-8.09(m, 3H), 7.71(d, 2H, J=8.1Hz),] in CDCl ₃ mp: 190°C (sublimed)
108	3-CF ₃	H	H	CO ₂ H	58	δ: [8.27-8.08(m, 3H), 7.79-7.49(m, 2H)] in CDCl ₃ mp: 198-200°C
109	3-NO ₂	H	H	CO ₂ H	80	δ: [13.25(br.s, 1H), 8.73(dd, 1H, J=1.6, 2.3Hz), 8.60(s, 1H), 8.42-8.34(m, 2H), 7.84(dd, 1H, J=7.9, 8.2Hz) in DMSO-d ₆ mp: 221-222°C
110	4-CO- 	H	H	CO ₂ H	35	δ: [8.50(s, 1H), 8.15-7.70(m, 9H) in CDCl ₃]

EP 0 513 379 B1

Pharmacological Test 1 (in vitro determination)

(1) Preparation of test compounds:

5 Test compounds (compounds of Ex. No. listed in Table 1) were dissolved in dimethylsulfoxide and diluted with a 50 mM phosphate buffer to prepare aqueous solutions respectively having predetermined concentrations.

(2) Determining method:

10 45 nmol of xanthine and test compounds prepared so as to have various concentrations were added to 3 ml of a phosphate buffer having a pH value of 7.4 and containing 3 mU of xanthine oxidase (derived from a butter milk; available from Sigma Chemical Company). A reaction was allowed to proceed at 37°C, and the change in OD at 292 nm based on the formation of uric acid was measured with time through the use of a spectrophotometer U-3200 (manufactured by Hitachi, Limited) to determine the initial reaction rate. The inhibition rate was determined by the following equation:
15

$$\text{Inhibition (\%)} = \frac{(\text{initial rate of control}) - (\text{initial rate in the case where inhibitor was added})}{(\text{initial rate of control})} \times 100$$

The inhibition (%) was determined on each test compound prepared according to (1), and the IC₅₀ value on the xanthine oxidase (XOD) inhibition was calculated from the value of inhibition. The results are given in Table 1.
20

25

30


35

40

45

50

55

Table 1





Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
Control	allopurinol				1.6×10^{-6}
1	3-O-iso-Pr	H	H	CH ₃	6.7×10^{-8}
2	4-O-iso-Pr	H	H	CH ₃	2.8×10^{-8}
3	3-NO ₂	H	H	CH ₃	1.4×10^{-8}
4	4-NO ₂	H	H	CH ₃	9.0×10^{-7}
5	3-CF ₃	H	H	CH ₃	6.3×10^{-10}
6	4-CF ₃	H	H	CH ₃	3.1×10^{-7}
7	4-OCH ₂ - 	H	H	CH ₃	4.6×10^{-8}
8	4-O(CH ₂) ₃ - 	H	H	CH ₃	3.2×10^{-9}
9	4-OCH ₂ -  -Cl	H	H	CH ₃	1.7×10^{-8}
10	4-OCH ₂ -  -F	H	H	CH ₃	3.1×10^{-8}
11	4-OCH ₂ COOH	H	H	CH ₃	7.7×10^{-8}
12	4-O(CH ₂) ₄ COOH	H	H	CH ₃	1.2×10^{-8}
13	3-COOH	H	H	CH ₃	3.2×10^{-7}

Table 1 (continuous)






Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
14	4-COOH	H	H	CH ₃	3.2 × 10 ⁻⁹
15	3-CONH-  -Cl	H	H	CH ₃	1.5 × 10 ⁻⁷
16	4-CONH-  -Cl	H	H	CH ₃	3.8 × 10 ⁻¹⁰
17	4-CON(CH ₃)-  -Cl	H	H	CH ₃	5.0 × 10 ⁻⁷
18	4-N(CH ₃) ₂	H	H	CH ₃	4.3 × 10 ⁻⁸
19	3-CO- 	H	H	CH ₃	1.2 × 10 ⁻⁸
20	4-CO- 	H	H	CH ₃	6.0 × 10 ⁻⁹
21	3-Cl	H	H	OH	7.2 × 10 ⁻⁷
22	4-O-iso-Pr	H	H	OH	4.5 × 10 ⁻⁸
23	4-O-iso-Pr	H	H	OCH ₃	1.3 × 10 ⁻⁷
24	2-Cl	5-NO ₂	H	CH ₃	6.7 × 10 ⁻⁸
25	3-Ac	4-OH	H	CH ₃	3.0 × 10 ⁻⁷
26	3-CF ₃	5-CF ₃	H	CH ₃	5.7 × 10 ⁻⁹
27	3-Cl	5-Cl	H	CH ₃	1.0 × 10 ⁻⁸
28	3-Cl	4-OH	5-Cl	CH ₃	2.6 × 10 ⁻⁸
29	3-tert-Bu	4-OH	5-tert-Bu	CH ₃	6.5 × 10 ⁻⁸

Table 1 (continuous)









Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
30	3-CH ₃	4-OH	5-CH ₃	CH ₃	4.2 × 10 ⁻⁸
31	3-NO ₂	4-O-iso-Pr	H	CH ₃	5.7 × 10 ⁻¹⁰
32	3-NO ₂	4-OCH ₂ - 	H	CH ₃	1.8 × 10 ⁻¹⁰
33	3-NO ₂	4-OEt	H	CH ₃	3.6 × 10 ⁻¹⁰
34	3-NO ₂	4-O-iso-Bu	H	CH ₃	2.4 × 10 ⁻⁹
35	3-NO ₂	4-S-iso-Pr	H	CH ₃	3.0 × 10 ⁻¹⁰
36	3-NO ₂	4-S-  -Cl	H	CH ₃	2.0 × 10 ⁻¹¹
37	3-NO ₂	4-NEt ₂	H	CH ₃	1.8 × 10 ⁻⁹
38	3-NO ₂	4-N- 	H	CH ₃	1.8 × 10 ⁻⁹
39	3-NO ₂	4-O(CH ₂) ₂ OEt	H	CH ₃	2.9 × 10 ⁻⁹
40	3-NO ₂	4-O- 	H	CH ₃	6.7 × 10 ⁻¹⁰
41	3-NO ₂	4-O(CH ₂) ₅ CH ₃	H	CH ₃	3.2 × 10 ⁻¹⁰
42	3-NO ₂	4-O- 	H	CH ₃	2.0 × 10 ⁻⁹
43	3-NO ₂	4-O- 	H	CH ₃	6.4 × 10 ⁻¹⁰
44	3-NO ₂	4-N- 	H	CH ₃	1.6 × 10 ⁻⁹
45	3-NO ₂	4-N- 	H	CH ₃	1.8 × 10 ⁻⁹

Table 1 (continuous)











Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
46	3-NO ₂	4-N  N-Me	H	CH ₃	2.4 × 10 ⁻⁹
49	3-Cl	4-OEt	H	CH ₃	2.3 × 10 ⁻⁹
50	3-Cl	4-O-isoPr	H	CH ₃	2.4 × 10 ⁻⁹
51	3-Cl	4-S-isoBu	H	CH ₃	2.1 × 10 ⁻⁹
52	3-Cl	4-O 	H	CH ₃	2.7 × 10 ⁻⁹
53	3-Cl	4-O 	H	CH ₃	2.7 × 10 ⁻⁹
54	3-Cl	4-O 	H	CH ₃	2.9 × 10 ⁻⁹
55	3-Cl	4-O(CH ₂) ₂ OEt	H	CH ₃	7.0 × 10 ⁻⁹
56	3-Cl	4-O 	H	CH ₃	1.5 × 10 ⁻⁹
57	3-Cl	4-O 	H	CH ₃	1.2 × 10 ⁻⁹
58	3-Cl	4-OCH ₂ - 	H	CH ₃	3.4 × 10 ⁻⁹
59	3-Cl	4-N 	H	CH ₃	3.8 × 10 ⁻¹⁰
60	3-Cl	4-N 	H	CH ₃	2.4 × 10 ⁻¹⁰
61	3-Cl	4-S- 	H	CH ₃	2.0 × 10 ⁻⁹

Table 1 (continuous)
















Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
62	3-Cl	4-SO-  -Cl	H	CH ₃	6.4 × 10 ⁻¹⁰
63	3-Br	4-O-isoBu	H	CH ₃	9.4 × 10 ⁻¹⁰
64	3-Br	4-O(CH ₂) ₂ OEt	H	CH ₃	2.9 × 10 ⁻⁹
65	3-Br	4-S-  -Cl	H	CH ₃	1.6 × 10 ⁻⁹
66	3-Br	4-N- 	H	CH ₃	6.3 × 10 ⁻¹⁰
67	3-F	4-O-isoBu	H	CH ₃	1.5 × 10 ⁻⁹
68	3-Cl	4-O-isoPr	5-Cl	CH ₃	2.2 × 10 ⁻⁹
69	3-Cl	4-O-isoBu	5-Cl	CH ₃	1.5 × 10 ⁻⁹
70	3-Cl	4-O- 	5-Cl	CH ₃	8.0 × 10 ⁻¹⁰
71	3-Cl	4-O- 	5-Cl	CH ₃	1.5 × 10 ⁻⁹
72	3-Cl	4-O- 	5-Cl	CH ₃	7.0 × 10 ⁻¹⁰
73	4-CO- 	H	H	CH ₃	6.2 × 10 ⁻⁹
74	4-CO- 	H	H	CH ₃	4.8 × 10 ⁻⁹
75	4-CO- 	H	H	CH ₃	8.3 × 10 ⁻¹⁰

Table 1 (continuous)

Example No.	R ₁	R ₂	R ₃	Y	IC ₅₀ (M)
76	3-CN	4-O-isoPr	H	CH ₃	9.3×10^{-10}
77	3-CN	4-O-isoBu	H	CH ₃	1.8×10^{-9}
78	3-CN	4-O- 	H	CH ₃	1.9×10^{-9}
79	3-CN	4-O- 	H	CH ₃	2.2×10^{-9}
80	3-CN	4-O(CH ₂) ₂ OEt	H	CH ₃	1.9×10^{-9}
81	3-CN	4-N- 	H	CH ₃	1.7×10^{-9}
82	3-CN	4-N- 	H	CH ₃	2.7×10^{-9}
83	3-CF ₃	4-O-isoBu	H	CH ₃	1.1×10^{-9}
84	3-CF ₃	4-O- 	H	CH ₃	2.9×10^{-9}
85	3-I	4-O- 	H	CH ₃	1.2×10^{-10}
86	3-CHO	4-O-isoBu	H	CH ₃	5.1×10^{-10}

Pharmacological Test 2 (Determination of Oral Administration)

Test compounds suspended in a 5% gum arabic solution was forcibly administered by oral administration (compounds of Ex. No. of Table 2, dose: 1 mg/kg) to ICR male mice (age: about 7 weeks) (one group: 6 mice) by means of an oral probe. 2 hours after the administration, thoracotomy was conducted under etherization to collect blood from the heart, and serum was removed by a conventional process. The serum uric acid was measured by a biochemical automatic analyzer (Flexigem; Electro-Nucleonics, Inc.) by using a uric acid measurement kit (UA reagent; International Reagent) to determine the percentage of the lowering of uric acid.

$$\text{Lowering in uric acid (\%)} = \frac{(\text{uric acid level of control animal}) - (\text{uric acid level of test-compound-administration animal})}{\text{uric acid level of object animal}} \times 100$$

The results are given in Table 2.

Table 2



Example No.	Activity of lowering uric acid (%)	Example No.	Activity of lowering uric acid (%)
allopurinol	73	33	71
5	37	34	76
8	28	35	57
16	21	36	14
18	22	37	74
20	18	38	91
26	63	39	82
31	90	40	85
32	48	41	92

Table 2 (continuous)

Example No.	Activity of lowering uric acid (%)	Example No.	Activity of lowering uric acid (%)
42	75	59	62
43	85	60	55
44	83	61	32
45	88	62	35
46	75	63	35
47	92	64	25
48	88	65	42
49	35	66	65
50	20	67	50
51	78	68	13
52	47	69	55
53	29	70	15
54	12	71	50
55	45	72	48
56	50	73	18
57	15	74	39
58	18	75	33

Table 2 (continuous)

Example No.	Activity of lowering uric acid (%)	Example No.	Activity of lowering uric acid (%)
76	86	82	93
77	95	83	86
78	91	84	80
79	89	85	77
80	87	86	72
81	91		

Pharmacological Test 3 (Interleukin 1 Production Inhibitory Activity)

1 ml of a 5% oyster glycogen solution was intra-abdominally administered to a BALB/c mouse (male, 8 weeks in age), and 4 days after the administration, the infiltrated abdominal exuded cells were adhered to a plastic dish for 2 hours, and 1 μ g/ml of LPS was allowed to act on macrophage (1×10^6 cells). Interleukin 1 extricated on the supernatant in 24 hours was measured by an ELISA technique. The test compound (compounds of Ex. No. described in Table 3) was prepared so as to have a concentration of 10^{-6} M, and the interleukin 1 production inhibitory activity was expressed in terms of the percentage inhibition based on the amount of production of the control. The results are given in Table 3.

Table 3

EP 0 513 379 B1

5	Example No.	Interleukin 1 production inhibitory activity (%)
	1	83
10	5	60
	6	38
	7	39
15	11	23
	12	42
	14	35
	15	38
20	20	65
	22	45
	26	57
25	27	43
	28	52
	40	36
	43	39
30	44	22
	45	18
	49	48
35	50	42
	52	33
	58	19
	64	28
40	67	48
	73	65
	74	52
45	75	48

Pharmacological Test 4 (Collagen Arthritis Inhibitory Activity)

50 An emulsion comprising a bovine II type collagen and incomplete Freund's adjuvant in a proportion of 1 : 1 were intradermally injected to Lewis rats (male, about 6 weeks in age) (one group: 8 mice) at the region of the back so that the amount of antigen was 2 mg/rat, thereby inducing arthritis. The compound of Ex. No. 35 was suspended in a 5% gum arabic solution, and orally administered 5 times per week in two groups of 10 mg/kg and 50 mg/kg from the sensi-
 55 tized day. Only the gum arabic solution was administered to the control. Then 6 weeks after the sensitization, the percentage increase in the volume of the right foot was measured and expressed in terms of the percentage swelling, and the anti-collagen antibody titer of the serum was measured by the ELISA technique. The results are given in Table 4.

As can be seen from Table 5, the compound of the present invention inhibited the swelling of foot-pad depending upon the dose when administered in doses of 100 mg/kg and 50 mg/kg (the percentage inhibitions were respectively

EP 0 513 379 B1

44.1% and 53.4%). Further, the compound of the present invention exhibited a tendency to inhibit the antibody titer of serum anti-collagen involved in the sideration of collagen arthritis in a group of administration in doses of 10 mg/kg and 50 mg/kg. The above-described facts suggest that there is a possibility that the compound of the present invention has an anti-arthritic activity and an anti-collagen-antibody is involved in one of the action mechanisms.

Table 4

	Dose (mg/kg)	Swelling (%)	Antibody titer of anti-collagen (μ U/ml)
control		45.5 \pm 5.1	2.04 \pm 0.36
compound of	10	25.4 \pm 5.3*	1.88 \pm 0.20
Ex. No. 73	50	21.2 \pm 4.2**	1.68 \pm 0.32

Note) *: P < 0.05 **: P < 0.01

Pharmaceutical Preparation Example 1

Tablets wherein one tablet had the following composition were prepared.

Compound prepared in Ex. 31	50 mg
Lactose	230 mg
Potato starch	80 mg
Polyvinyl pyrrolidone	11 mg
Magnesium stearate	5 mg
	376 mg

The compound of the above-described Example, lactose and potato starch were mixed with each other, and a 20% ethanol solution of polyvinyl pyrrolidone was evenly infiltrated into the mixture, passed through a 20 nm mesh sieve, dried at 45°C, and again passed through a 15 nm mesh sieve. The granules thus prepared were mixed with magnesium stearate, and the mixture was compressed into a tablet.

Pharmaceutical Preparation Example 2

The pharmaceutical preparation example 2 was repeated, except that the compound prepared in Ex. 69 was used instead of that in Ex. 31.


[Industrial Applicability]

In accordance with the present invention, pharmaceutical compositions containing a 2-arylthiazole derivative or a pharmaceutically acceptable salt thereof, which is efficacious for a treatment of gout or hyperuricemia, are provided. Accordingly, the present invention is applicable to the manufacture of pharmaceutical compositions.

Claims

Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, IT, NL, SE


1. A pharmaceutical composition comprising an effective amount of a 2-arylthiazole derivative having the following formula (I) or a pharmaceutically acceptable salt thereof for treating gout or hyperuricemia and diseases associated with the production of interleukin 1:



(I)

wherein

Ar represents an unsubstituted or substituted pyridyl, thienyl, furyl or naphthyl group, or a group having the following formula (II)



(II)

wherein

at least one group of R_1 , R_2 and R_3 is hydrogen or a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR , $S(O)_nR$ and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R' , taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), or a group of COR'' (wherein R'' represents an unsubstituted or substituted C_{1-10} alkyl, aryl or aralkyl group; a hydroxyl group; an unsubstituted or substituted C_{1-10} alkoxy, aryloxy or aralkyloxy group; an amino group; or an unsubstituted or substituted C_{1-10} alkyl (mono- or di-substituted, independently) amino, aryl (mono- or di-substituted, independently) amino or aralkyl (mono- or di-substituted, independently) amino group, or a 5- to 7- membered cyclic amino group);

X represents a hydrogen atom, or a C_{1-4} alkyl, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group; and


Y represents a hydrogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group,

with the proviso that when at least one group of R_1 , R_2 and R_3 represents a halogen atom, or an alkoxy, alkylamino or nitro group, at least one group of the two other groups represents a group other than hydrogen; when at least one group of R_1 , R_2 and R_3 is a halogen atom and another group is a hydrogen atom, the remaining group is a group other than a halogen, or an alkoxy, alkylamino or acylamino group; and R_1 , R_2 and R_3 are not all methoxy at the same time.

2. A pharmaceutical composition in accordance with claim 1, wherein Ar is a group of the formula (II), and at least one group of R_1 , R_2 and R_3 is a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR , $S(O)_nR$ or NRR' (wherein n is an integer of from 0 to 2, R is an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, and R' is a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R' , taken together with the nitrogen atom bonded thereto, are atoms forming an unsubstituted or substituted 5- to 7-membered heterocyclic ring), or a group of COR'' (wherein R'' is an unsubstituted or substituted C_{1-10} alkyl, aryl, or aralkyl group, a hydroxyl group, an unsubstituted or substituted C_{1-10} alkoxy, aryloxy or aralkyloxy group, an amino group, or an unsubstituted or substituted C_{1-10} alkyl (mono- or di-substituted, independently) amino, aryl (mono- or di-substituted, independently) amino or aralkyl (mono- or di-substituted, independently) amino group, or a 5- to 7- membered cyclic amino group);

X is a carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group.

3. A 2-arylthiazole derivative having the following formula (I), or a pharmaceutically acceptable salt thereof:



wherein

Ar is an unsubstituted or substituted pyridyl, thienyl, furyl or naphthyl group; or a group represented by the following formula (II)



wherein

at least one group of R_1 , R_2 and R_3 is hydrogen, a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR , $S(O)_nR$ and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R' , taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), or a group of COR'' (wherein R'' represents an unsubstituted or substituted C_{1-10} alkyl, aryl or aralkyl group; a hydroxyl group; an unsubstituted or substituted C_{1-10} alkoxy, aryloxy or aralkyloxy group; an amino group; or an unsubstituted or substituted C_{1-10} alkyl (mono- or di-substituted, independently) amino, aryl (mono- or di-substituted, independently) amino or aralkyl (mono or di-substituted, independently) amino group, or a 5- to 7- membered cyclic amino group);

X is a hydrogen atom, or a C_{1-4} alkyl, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group; and

Y represents a hydrogen atom, or a C_{1-4} alkyl, C_{1-4} alkoxy, carboxyl, C_{1-5} alkoxycarbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group,

with the proviso that when at least one group of R_1 , R_2 and R_3 represents a halogen atom, or an alkoxy, alkylamino or nitro group, at least one group of the two other groups represents a group other than hydrogen; when at least one group of R_1 , R_2 and R_3 is a halogen atom and another group is a hydrogen atom, the remaining group is a group other than a halogen atom, or an alkoxy, alkylamino or acylamino group; and

when R_1 , R_2 and R_3 are not all methoxy at the same time.

4. A 2-arylthiazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof in accordance with claim 3, wherein Ar represents a group of the formula (II), and R_1 is a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group, R_2 is a trifluoromethyl group or a group of OR , $S(O)_nR$ or NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R' , taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7-membered heterocyclic ring), and R_3 represents a hydrogen or halogen atom.

5. A 2-arylthiazole derivative or a pharmaceutically acceptable salt thereof in accordance with claim 4, wherein X is a carboxyl, C_{1-5} alkoxy-carbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group; and Y is a hydrogen atom, or a C_{1-4} alkyl or C_{1-4} alkoxy group.

6. A 2-arylthiazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof in accordance with claim 3, wherein Ar represents a group of the formula (II), and R_1 represents a m-nitro or m-cyano group, R_2 represents a group of OR , $S(O)_nR$ and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C_{1-10} alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or

R and R', taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), and R₃ represents a hydrogen atom;

X represents a carboxyl, C₁₋₅ alkoxy carbonyl, carbamoyl or C₁₋₄ alkyl (mono- or di- substituted) aminocarbonyl group; and

Y represents a hydrogen atom, or a C₁₋₄ alkyl or C₁₋₄ alkoxy group.

7. A 2-arylthiazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof in accordance with claim 3, wherein Ar represents a group of the formula (II), and R¹ represents a m-halogen atom or a m-trifluoromethyl group, R₂ represents a group of OR, S(O)_nR and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), and R₃ represents a hydrogen or halogen atom.

8. A 2-arylthiazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof in accordance with claim 3, wherein Ar represents a group of the formula (II), and R₁ represents a m-halogen atom, R₂ represents a group of OR, S(O)_nR and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl; or R and R', taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), and R₃ represents a hydrogen or halogen atom;

X represents a carboxyl, C₁₋₅ alkoxy carbonyl, carbamoyl or C₁₋₄ alkyl (mono- or di-substituted)- aminocarbonyl group; and


Y represents a C₁₋₄ alkyl or C₁₋₅ alkoxy group.

9. A 2-arylthiazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof in accordance with claim 3, wherein Ar represents a group of the formula (II), and R₁ represents a group of COR'' (wherein R'' represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl or aralkyl group);

X represents a carboxyl, C₁₋₅ alkoxy carbonyl, carbamoyl or C₁₋₄ alkyl (mono- or di-substituted) aminocarbonyl group; and

Y represents a hydrogen atom, or a C₁₋₄ alkyl or C₁₋₅ alkoxy group.

10. A 2-arylthiazole derivative of the following formula (I-a) or a pharmaceutically acceptable salt thereof in accordance with claim 3:



(I - a)

wherein

R_{1-a} is a C₂₋₈ alkoxy group and R_{2-a} is a nitro group;

R_{1-a} is a C₂₋₈ alkoxy group and R_{2-a} is a trifluoromethyl group;


R_{1-a} is a morpholino, 4-N-methylpiperazine-1-yl or piperidino group and R_{2-a} is a nitro group;

R_{1-a} is a morpholino, 4-N-methylpiperazine-1-yl or piperidino group and R_{2-a} is a cyano group;

R_{1-a} is a C₂₋₈ alkoxy group and R_{2-a} is a cyano group; or

R_{1-a} is an unsubstituted benzoyl group or a benzoyl substituted by one or two of a methyl group, chlorine atom or methoxy group, and R_{2-a} is a hydrogen atom.

11. A 2-arylthiazole derivative of the following formula (I-b) or a pharmaceutically acceptable salt thereof in accordance with claim 4:




(I - b)

wherein

R_{1-b} is a group of OR and SR (wherein R represents a C₂₋₈ alkyl, morpholino, 4-N-methyl piperazine-1-yl or piperidino group); R_{2-b} represents a nitro, trifluoromethyl or cyano group, and Y_b represents a hydrogen atom or a methyl group; and


R_{1-b} represents a group of the formula



(wherein R_{3-b} represents an unsubstituted or substituted phenyl group; R_{4-b} represents a hydrogen atom or a C₁₋₃ alkyl group, and Y_b represents a hydrogen atom or a methyl group).

Claims for the following Contracting State : ES


1. A process for the preparation of 2-arylthiazole derivatives having the formula:-



(I)

wherein

Ar represents a group having the following formula (II)



(II)

wherein


at least one group of R₁, R₂ and R₃ is hydrogen or a halogen atom, or a nitro, cyano, formyl or trifluoromethyl group; or a group of OR, S(O)_nR and NRR' (wherein n is an integer of from 0 to 2, R represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group, R' represents a hydrogen atom, or an unsubstituted or substituted C₁₋₁₀ alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl or aralkylcarbonyl group; or R and R', taken together with the nitrogen atom bonded thereto, represent atoms forming an unsubstituted or substituted 5- to 7- membered heterocyclic ring), or a group of COR'' (wherein R'' represents an unsubstituted or substituted C₁₋₁₀ alkyl, aryl or aralkyl group; a hydroxyl group; an unsubstituted or substituted C₁₋₁₀ alkoxy, aryloxy or aralkyloxy group; an amino group; or an unsubstituted or substituted C₁₋₁₀ alkyl (mono- or di-substituted, independently) amino, aryl (mono- or di-substituted, independently) amino or aralkyl (mono- or di-substituted, independently) amino group, or a 5- to 7- membered cyclic amino group);

EP 0 513 379 B1

X represents the group COOR_a where R_a is a C_{1-4} alkyl group; and

Y represents a hydrogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy, carboxyl, C_{1-5} alkoxy-carbonyl, carbamoyl or C_{1-4} alkyl (mono- or di-substituted) aminocarbonyl group,

with the proviso that when at least one group of R_1 , R_2 and R_3 represents a halogen atom, or an alkoxy, alkylamino or nitro group, at least one group of the two other groups represents a group other than hydrogen; when at least one group of R_1 , R_2 and R_3 is a halogen atom and another group is a hydrogen atom, the remaining group is a group other than a halogen, or an alkoxy, alkylamino or acylamino group; and R_1 , R_2 and R_3 are not all methoxy at the same time. characterised in that the compounds are produced according to the following reaction:




wherein R_a is as defined above in connection with formula (I), R_1 , R_2 and R_3 are as defined above in connection with formula (II), Y is as defined above in connection with formula (I), and Hal represents a halogen atom.

2. A process according to Claim 1, characterised in that the substituted thiobenzamide and an alkyl ester of 2-haloacetic acid are directly mixed in a solvent at a temperature of between room temperature and 200°C .
3. A process according to Claim 2, characterised in that a base is present in the reaction mixture.
4. A process according to Claim 3, characterised in that the base is organic and is selected from triethylamine, pyridine and dimethylaminopyridine.
5. A process according to Claim 3, characterised in that the base is inorganic and is selected from anhydrous potassium carbonate and sodium hydroxide.
6. A process according to any of Claims 2 to 5, characterised in that the solvent is a hydrocarbon, an ether, an alcohol, N,N dimethylformamide, dimethylsulfoxide or acetonitrile.
7. A process according to any of Claims 1 to 6, followed by hydrolysis to produce the corresponding carboxylic acid.

Patentansprüche


Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, DK, FR, GB, IT, NL, SE

1. Pharmazeutische Zusammensetzung mit einer wirksamen Menge eines 2-Arylthiazol-Derivates mit der folgenden Formel (I) oder einem pharmazeutisch geeigneten Salz hiervon zur Behandlung von Gicht oder Hyperurikämie und Krankheiten, welche mit der Produktion von Interleukin 1 in Verbindung stehen:



(I)

worin Ar einen unsubstituierten oder substituierten Pyridyl-, Thienyl-, Furyl- oder Naphthyl-Rest oder einen Rest mit der folgenden Formel (II) bedeutet:




(II)

5
10
15
20
25
30

worin mindestens eine der Gruppen R_1 , R_2 und R_3 Wasserstoff oder ein Halogenatom ist oder eine Nitro-, Cyano-, Formyl- oder Trifluoromethyl-Gruppe; oder eine Gruppe OR , $S(O)_nR$ und NRR' (worin n eine ganze Zahl von 0 bis 2 ist, worin R einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder einen substituierten oder unsubstituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest repräsentiert; oder worin R und R' zusammen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden); oder eine Gruppe COR'' (worin R'' einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl- oder Aralkyl-Rest; eine Hydroxyl-Gruppe; eine substituierte oder unsubstituierte C_1 - C_{10} Alkoxy-, Aryloxy- oder Aralkyloxy-Gruppe; eine Amino-Gruppe; oder einen unsubstituierten oder substituierten C_1 - C_{10} -Alkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig), einen Arylamino-Rest (mono- oder di-substituiert, jeweils unabhängig) oder einen Aralkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig) oder eine 5- bis 7-gliedrige zyklische Amino-Gruppe repräsentiert); worin X ein Wasserstoffatom oder eine C_1 - C_4 Alkyl-, Carboxyl-, C_1 - C_5 Alkoxy-carbonyl-, Carbamoyl- oder C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert; und worin Y ein Wasserstoffatom oder eine C_1 - C_4 -Alkyl-, eine C_1 - C_4 -Alkoxy-, Carboxyl-, C_1 - C_5 -Alkoxy-carbonyl-, einen Carbamoyl oder eine C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert, unter der Voraussetzung, daß wenn mindestens eine der Gruppen von R_1 , R_2 und R_3 ein Halogenatom oder eine Alkoxy-, eine Alkylamino- oder Nitrogruppe repräsentiert mindestens eine Gruppe der zwei anderen Gruppen eine Gruppe, die von Wasserstoff verschieden ist, repräsentiert; daß wenn mindestens eine der Gruppen R_1 , R_2 und R_3 ein Halogenatom ist und eine andere Gruppe ein Wasserstoffatom ist, die verbleibende Gruppe eine Gruppe bedeutet, welche von Halogen, einer Alkoxy-, Alkylamino- oder Acylamino-Gruppe verschieden ist; und daß R_1 , R_2 und R_3 nicht alle gleichzeitig Methoxy bedeuten.


2. Pharmazeutische Zusammensetzung nach Anspruch 1, worin Ar eine Gruppe der Formel II ist und mindestens eine der Gruppen R_1 , R_2 und R_3 ein Halogenatom bedeutet oder eine Nitro-, Cyano-, Formyl- oder Trifluoromethylgruppe; oder eine Gruppe OR , $S(O)_nR$ oder NRR' (worin n eine ganze Zahl von 0 bis 2 ist, R eine unsubstituierte oder substituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe bedeutet und R' ein Wasserstoffatom oder eine unsubstituierte oder substituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe bedeutet; oder worin R und R' zusammengekommen mit dem Stickstoffatom, das an sie gebunden ist, Atome darstellen, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden) oder eine Gruppe COR'' , worin R'' eine unsubstituierte oder substituierte C_1 - C_{10} -Alkyl-, Aryl- oder Aralkyl-Gruppe, eine Hydroxylgruppe, einen unsubstituierten oder substituierten C_1 - C_{10} -Alkoxy-, Aryloxy- oder Aralkyloxy-Rest, eine Amino-Gruppe oder einen unsubstituierten oder substituierten C_1 - C_{10} -Alkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig), eine Arylamino-Gruppe (mono- oder di-substituiert, jeweils unabhängig) oder Aralkylamino (mono- oder di-substituiert, jeweils unabhängig) oder eine 5- bis 7-gliedrige zyklische Aminogruppe repräsentiert); worin X eine Carboxyl-, eine C_1 - C_5 -Alkoxy-carbonyl-, eine Carbamoyl- oder eine C_1 - C_4 -Alkylaminocarbonylgruppe (mono- oder di-substituiert) bedeutet.

3. 2-Arylthiazolderivat mit der folgenden Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon:



(I)

worin Ar einen unsubstituierten oder substituierten Pyridyl-, Thienyl-, Furyl- oder Naphthyl-Rest oder einen Rest mit der folgenden Formel (II) bedeutet



(II)


worin mindestens eine der Gruppen R_1 , R_2 und R_3 Wasserstoff, ein Halogenatom oder eine Nitro-, Cyano-, Formyl- oder Trifluoromethyl-Gruppe bedeutet; oder eine Gruppe OR , $S(O)_nR$ und NRR' (worin n eine ganze Zahl von 0 bis 2 ist, worin R einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder einen substituierten oder unsubstituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest repräsentiert; oder worin R und R' zusammen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden), oder einen Gruppe an COR'' (worin R'' einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl- oder Aralkyl-Rest; eine Hydroxyl-Gruppe; eine substituierte oder unsubstituierte C_1 - C_{10} -Alkoxy-, Aryloxy- oder Aralkyloxy-Gruppe; eine Amino-Gruppe; oder einen unsubstituierten oder substituierten C_1 - C_{10} -Alkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig), einen Arylamino-Rest (mono- oder di-substituiert, jeweils unabhängig) oder einen Aralkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig) oder eine 5- bis 7-gliedrige zyklische Aminogruppe repräsentiert); worin X ein Wasserstoffatom oder eine C_1 - C_4 -Alkyl-, Carboxyl-, C_1 - C_5 -Alkoxy-carbonyl-, Carbamoyl- oder C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert; und worin Y ein Wasserstoffatom oder eine C_1 - C_4 -Alkyl-, eine C_1 - C_4 -Alkoxy-, Carboxyl-, C_1 - C_5 -Alkoxy-carbonyl-, einen Carbamoyl oder eine C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert, unter Voraussetzung, daß wenn mindestens eine der Gruppen von R_1 , R_2 und R_3 ein Halogenatom oder eine Alkoxy-, eine Alkylamino- oder Nitrogruppe repräsentiert mindestens eine Gruppe der zwei anderen Gruppen eine Gruppe, die von Wasserstoff verschieden ist, repräsentiert; daß wenn mindestens eine der Gruppen R_1 , R_2 und R_3 ein Halogenatom ist und eine andere Gruppe ein Wasserstoffatom ist, die verbleibende Gruppe eine Gruppe bedeutet, welche von Halogen, einer Alkoxy-, Alkylamino- oder Acylamino-Gruppe verschieden ist; und daß R_1 , R_2 und R_3 nicht alle gleichzeitig Methoxy bedeuten.

4. 2-Arylthiazolderivat der Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3, worin Ar eine Gruppe der Formel (II) repräsentiert und R_1 ein Halogenatom ist oder eine Nitro-, Cyano-, Formyl- oder Trifluoromethylgruppe, worin R_2 ein Trifluoromethylgruppe oder eine Gruppe OR , $S(O)_nR$ oder NRR' bedeutet (worin n eine ganze Zahl von 0 bis 2 ist, worin R ein unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder eine substituierte oder unsubstituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe bedeutet; oder worin R und R' zusammengekommen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden) und worin R_3 einen Wasserstoff oder ein Halogenatom repräsentiert.

5. 2-Arylthiazolderivat oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 4, worin X eine Carboxyl-, C_1 - C_5 -Alkoxy-Carbonyl-, eine Carbamoyl-, eine C_1 - C_4 -Alkylaminocarbonylgruppe (mono- oder di-substituiert) repräsentiert; und worin Y ein Wasserstoffatom oder eine C_1 - C_4 Alkyl- oder C_1 - C_4 -Alkoxy-Gruppe bedeutet.


6. 2-Arylthiazolderivat der Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3, worin Ar eine Gruppe der Formel (II) repräsentiert und R_1 eine m -Nitro- oder m -Cyano-Gruppe bedeutet, worin R_2 eine Gruppe OR , $S(O)_nR$ oder NRR' repräsentiert (worin n eine ganze Zahl von 0 bis 2 ist, R einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder eine substituierte oder unsubstituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe repräsentiert; oder worin R und R' zusammengekommen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden) und worin R_3 ein Wasserstoffatom repräsentiert; worin X eine Carboxyl-, eine C_1 - C_5 -Alkoxy-carbonyl-, eine Carbamoyl- oder eine C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert; und worin Y ein Wasserstoffatom oder eine C_1 - C_4 -Alkyl- oder C_1 - C_4 -Alkoxygruppe repräsentiert.

7. 2-Arylthiazolderivat der Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3, worin Ar eine Gruppe der Formel (II) repräsentiert und R_1 ein m-Halogenatom oder eine m-Trifluoromethyl-Gruppe bedeutet, worin R_2 eine Gruppe OR, $S(O)_nR$ oder NR_1R' repräsentiert (worin n eine ganze Zahl von 0 bis 2 ist, R einen unsubstituierten oder substituierten C_1 - C_{10} Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder eine substituierte oder unsubstituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe repräsentiert; oder worin R und R' zusammengekommen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden), und worin R_3 einen Wasserstoff- oder ein Halogenatom repräsentiert.
8. 2-Arylthiazolderivat der Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3, worin Ar eine Gruppe der Formel (II) repräsentiert und worin R_1 ein m-Halogenatom bedeutet, R_2 eine Gruppe OR, $S(O)_nR$ oder NR_1R' repräsentiert (worin n eine ganze Zahl von 0 bis 2 ist, worin R einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder eine substituierte oder unsubstituierte C_1 - C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Gruppe repräsentiert; oder worin R und R' zusammengekommen mit dem daran gebundenen Stickstoffatom Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden), und worin R_3 einen Wasserstoff oder ein Halogenatom repräsentiert; worin X eine Carboxyl-, eine C_1 - C_5 -Alkoxycarbonyl-, eine Carbamoyl- oder eine C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert; und worin Y eine C_1 - C_4 -Alkyl- oder eine C_1 - C_5 -Alkoxygruppe repräsentiert.
9. 2-Arylthiazolderivat der Formel (I) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3, worin Ar eine Gruppe der Formel (II) repräsentiert, und worin R_1 eine Gruppe COR'' repräsentiert (worin R'' einen unsubstituierten oder substituierten C_1 - C_{10} -Alkyl-, Aryl- oder Aralkyl-Rest bedeutet); worin X eine Carboxyl-, eine C_1 - C_5 -Alkoxycarbonyl-, eine Carbamoyl- oder eine C_1 - C_4 -Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert; und worin Y ein Wasserstoffatom oder eine C_1 - C_4 -Alkyl- oder eine C_1 - C_5 -Alkoxygruppe repräsentiert.
10. 2-Arylthiazolderivat der folgenden Formel (I-a) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 3:




- worin R_{1-a} eine C_2 - C_8 -Alkoxy-Gruppe und R_{2-a} eine Nitro-Gruppe ist;
- R_{1-a} eine C_2 - C_8 -Alkoxy-Gruppe und R_{2-a} eine Trifluoromethyl-Gruppe ist;
- R_{1-a} eine Morpholino-, 4-N-Methylpiperazin-1-yl- oder eine Piperidino-Gruppe und R_{2-a} eine Nitro-Gruppe ist;
- R_{1-a} eine Morpholino-, 4-N-Methylpiperazin-1-yl- oder eine Piperidino-Gruppe und R_{2-a} eine Cyano-Gruppe ist;
- R_{1-a} ist eine C_2 - C_8 -Alkoxy-Gruppe und R_{2-a} eine Cyano-Gruppe ist; oder
- R_{1-a} eine unsubstituierte Benzoyl-Gruppe oder eine Benzoyl-Gruppe, substituiert mit 1 oder 2 Substituenten aus der Reihe einer Methylgruppe, einem Chloratom oder einer Methoxy-Gruppe und R_{2-a} ein Wasserstoffatom ist.

11. 2-Arylthiazolderivat der folgenden Formel (I-b) oder ein pharmazeutisch geeignetes Salz hiervon gemäß Anspruch 4:



worin R_{1-b} eine Gruppe OR oder SR ist (worin R eine C_2-C_8 -Alkyl-, eine Morpholino-, eine 4-N-Methylpiperazin-1-yl- oder Piperidino-Gruppe repräsentiert); worin R_{2-b} eine Nitro- eine Trifluoromethyl- oder eine Cyano-Gruppe repräsentiert und worin Y_b ein Wasserstoffatom oder eine Methyl-Gruppe repräsentiert; und worin R_{1-b} eine Gruppe der Formel



repräsentiert (worin R_{3-b} eine unsubstituierte oder substituierte Phenyl-Gruppe repräsentiert; worin R_{4-b} ein Wasserstoffatom oder eine C_1-C_3 -Alkyl-Gruppe repräsentiert, und worin Y_b ein Wasserstoffatom oder eine Methyl-Gruppe repräsentiert).

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung eines 2-Arylthiazol-Derivates mit der folgenden Formel (I)




worin Ar einen Rest mit der folgenden Formel (II) bedeutet:



worin mindestens eine der Gruppen R_1 , R_2 und R_3 Wasserstoff oder ein Halogenatom ist oder eine Nitro-, Cyano-, Formyl- oder Trifluoromethyl-Gruppe; oder eine Gruppe OR, $S(O)_nR$ und NRR' (worin n eine ganze Zahl von 0 bis 2 ist, worin R einen unsubstituierten oder substituierten C_1-C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest bedeutet, worin R' ein Wasserstoffatom oder einen substituierten oder unsubstituierten C_1-C_{10} -Alkyl-, Aryl-, Aralkyl-, Alkylcarbonyl-, Arylcarbonyl- oder Aralkylcarbonyl-Rest repräsentiert; oder worin R und R' zusammen mit dem Stickstoffatom, das an sie gebunden ist, Atome repräsentieren, welche einen unsubstituierten oder substituierten 5- bis 7-gliedrigen heterozyklischen Ring bilden); oder eine Gruppe COR'' (worin R'' einen unsubstituierten oder substituierten C_1-C_{10} -Alkyl-, Aryl- oder Aralkyl-Rest; eine Hydroxyl-Gruppe; eine substituierte oder unsubstituierte C_1-C_{10} Alkoxy-, Aryloxy- oder Aralkyloxy-Gruppe; eine Amino-Gruppe; oder einen

unsubstituierten oder substituierten C₁-C₁₀-Alkylamino-Rest (mono- oder di-substituiert, jeweils unabhängig),
 einen Arylamino-Rest (mono- oder di-substituiert, jeweils unabhängig) oder einen Aralkylamino-Rest (mono- oder
 di-substituiert, jeweils unabhängig) oder eine 5- bis 7-gliedrige zyklische Amino-Gruppe repräsentiert);
 worin X COOR_a-Gruppe repräsentiert, wobei R_a eine C₁-C₄ Alkyl-Gruppe repräsentiert; und
 worin Y ein Wasserstoffatom oder eine C₁-C₄-Alkyl-, eine C₁-C₄-Alkoxy-, Carboxyl-, C₁-C₅-Alkoxy-carbonyl-, einen
 Carbamoyl oder eine C₁-C₄-Alkylaminocarbonyl-Gruppe (mono- oder di-substituiert) repräsentiert,
 unter der Voraussetzung, daß wenn mindestens eine der Gruppen von R₁, R₂ und R₃ ein Halogenatom oder eine
 Alkoxy-, eine Alkylamino- oder Nitrogruppe repräsentiert mindestens eine Gruppe der zwei anderen Gruppen eine
 Gruppe, die von Wasserstoff verschieden ist, repräsentiert; daß wenn mindestens eine der Gruppen R₁, R₂ und R₃
 ein Halogenatom und eine andere Gruppe ein Wasserstoffatom ist, die verbleibende Gruppe eine Gruppe bedeu-
 tet, welche von Halogen, einer Alkoxy-, einer Alkylamino- oder einer Acylamino-Gruppe verschieden ist; und daß
 R₁, R₂ und R₃ nicht alle gleichzeitig Methoxy bedeuten, dadurch gekennzeichnet, daß die Verbindungen entspre-
 chend der folgenden Reaktionsgleichung hergestellt sind:




worin R_a wie oben im Zusammenhang mit der Formel (I) definiert ist, worin R₁, R₂ und R₃ wie oben im Zusammen-
 hang mit Formel (II) definiert sind, und worin Y wie oben im Zusammenhang mit Formel (I) definiert ist und Hal ein
 Halogenatom repräsentiert.

2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das substituierte Thiobenzamid und ein Alkylester einer
 2-Halogenaclessigsäure direkt in einem Lösemittel bei einer Temperatur zwischen Raumtemperatur und 200°C
 gemischt werden.
3. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß eine Base in der Reaktionsmischung vorhanden ist.
4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß die Base eine organische Base ist und ausgewählt ist
 aus Triethylamin, Pyridin und Dimethylaminopyridin.
5. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß die Base eine anorganische Base ist und ausgewählt
 ist aus wasserfreien Kaliumcarbonat und Natriumhydroxid.
6. Verfahren nach den Ansprüchen 2 bis 5, dadurch gekennzeichnet, daß das Lösemittel im Kohlenwasserstoff, ein
 Ether, ein Alkohol, N,N-Dimethylformamid, Dimethylsulfoxid oder Acetonitril ist.
7. Verfahren nach einem der Ansprüche 1 bis 6, gefolgt von einer Hydrolyse um die korrespondierende Carbonsäure
 herzustellen.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, LI, DE, DK, FR, GB, IT, NL, SE


1. Composition pharmaceutique comprenant une quantité efficace d'un dérivé de 2-arylthiazole ayant la formule (I)
 ci-dessous ou un des ses sels pharmaceutiquement acceptables pour le traitement de la goutte ou de l'hyperuri-
 cémie et des maladies associées à la production d'interleukine I:



(I)

dans laquelle

Ar représente un groupe pyridyle, thiényle, furyle ou naphthyle non substitué ou substitué, ou un groupe de formule (II) ci-dessous



(II)

dans laquelle au moins un des restes R_1 , R_2 et R_3 est un atome d'hydrogène ou d'halogène ou un groupe nitro, cyano, formyle ou trifluorométhyle; ou un groupe OR, $S(O)_nR$ ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C_1-C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, R' représente un atome d'hydrogène ou un groupe alkyle en C_1-C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R' , pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), ou un groupe COR'' (où R'' représente un groupe alkyle en C_1-C_{10} , aryle ou aralkyle, non substitué ou substitué; un groupe hydroxyle; un groupe alcoxy en C_1-C_{10} , aryloxy ou aralcoxy, non substitué ou substitué; un groupe amino; ou un groupe amino mono- ou disubstitué indépendamment par alkyle en C_1-C_{10} , amino mono- ou disubstitué indépendamment par aryle, ou amino mono- ou disubstitué indépendamment par aralkyle, substitué ou non substitué; ou un groupe amino cyclique de 5 à 7 chaînons);

X représente un atome d'hydrogène ou un groupe alkyle en C_1-C_4 , carboxyle, alcoxycarbonyle en C_1-C_5 , carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C_1-C_4 ; et

Y représente un atome d'hydrogène ou un groupe alkyle en C_1-C_4 , alcoxy en C_1-C_4 , carboxyle, alcoxycarbonyle en C_1-C_5 , carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C_1-C_4 ;

à condition que, lorsqu'au moins l'un des groupes R_1 , R_2 et R_3 représente un atome d'halogène ou un groupe alcoxy, alkylamino ou nitro, au moins l'un des deux autres groupes représente un groupe différent de l'hydrogène; et que, lorsqu'au moins l'un des groupes R_1 , R_2 et R_3 est un atome d'halogène et qu'un autre groupe est un atome d'hydrogène, le groupe restant soit un groupe différent d'un atome d'halogène ou d'un groupe alcoxy, alkylamino ou acylamino; et que R_1 , R_2 et R_3 ne soient pas tous en même temps des groupes méthoxy.

2. Composition pharmaceutique selon la revendication 1, dans laquelle Ar est un groupe de formule (II) et au moins l'un des groupes R_1 , R_2 et R_3 est un atome d'halogène ou un groupe nitro, cyano, formyle ou trifluorométhyle; ou un groupe OR, $S(O)_nR$ ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C_1-C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, et R' représente un atome d'hydrogène ou un groupe alkyle en C_1-C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R' , pris ensemble avec l'atome d'azote auquel ils sont liés, sont des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), ou un groupe COR'' (où R'' représente un groupe alkyle en C_1-C_{10} , aryle ou aralkyle, non substitué ou substitué; un groupe hydroxyle; un groupe alcoxy en C_1-C_{10} , aryloxy ou aralcoxy, non substitué ou substitué; un groupe amino; ou un groupe amino mono- ou disubstitué indépendamment par alkyle en C_1-C_{10} , amino mono- ou disubstitué indépendamment par aryle, ou amino mono- ou disubstitué indépendamment par aralkyle, substitué ou non substitué; ou un groupe amino cyclique de 5 à 7 chaînons);


X est un groupe carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄.

3. Dérivé de 2-arylthiazole ayant la formule (I) ci-dessous, ou un de ses sels pharmaceutiquement acceptables:



dans laquelle

Ar représente un groupe pyridyle, thiényle, furyle ou naphtyle non substitué ou substitué, ou un groupe de formule (II) ci-dessous



dans laquelle au moins un des restes R₁, R₂ et R₃ est un atome d'hydrogène ou d'halogène ou un groupe nitro, cyano, formyle ou trifluorométhyle; ou un groupe OR, S(O)_nR ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, R' représente un atome d'hydrogène ou un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R', pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), ou un groupe COR'' (où R'' représente un groupe alkyle en C₁-C₁₀, aryle ou aralkyle, non substitué ou substitué; un groupe hydroxyle; un groupe alcoxy en C₁-C₁₀, aryloxy ou aralcoxy, non substitué ou substitué; un groupe amino; ou un groupe amino mono- ou disubstitué indépendamment par alkyle en C₁-C₁₀, amino mono- ou disubstitué indépendamment par aryle, ou amino mono- ou disubstitué indépendamment par aralkyle, substitué ou non substitué; ou un groupe amino cyclique de 5 à 7 chaînons);

X représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄, carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄; et

Y représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄, alcoxy en C₁-C₄, carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄;

à condition que, lorsqu'au moins l'un des groupes R₁, R₂ et R₃ représente un atome d'halogène ou un groupe alcoxy, alkylamino ou nitro, au moins l'un des deux autres groupes représente un groupe différent de l'hydrogène; et que, lorsqu'au moins l'un des groupes R₁, R₂ et R₃ est un atome d'halogène et qu'un autre groupe est un atome d'hydrogène, le groupe restant soit un groupe différent d'un atome d'halogène ou d'un groupe alcoxy, alkylamino ou acylamino; et que R₁, R₂ et R₃ ne soient pas tous en même temps des groupes méthoxy.

4. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 3, dans lequel Ar représente un groupe de formule (II) et R₁ est un atome d'halogène ou un groupe nitro, cyano, formyle ou trifluorométhyle, R₂ est un groupe trifluorométhyle ou un groupe OR, S(O)_nR ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, et R' représente un atome d'hydrogène ou un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R', pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), et R₃ représente un atome d'hydrogène ou d'halogène.

5. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 4, dans lequel X est un groupe carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄; et Y est un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ou alcoxy en C₁-C₄.

6. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 3, dans lequel Ar représente un groupe de formule (II) et R₁ représente un groupe m-nitro ou m-cyano, R₂ est un groupe OR, S(O)_nR ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, et R' représente un atome d'hydrogène ou un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R', pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), et R₃ représente un atome d'hydrogène;

X représente un groupe carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄; et

Y représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ou alcoxy en C₁-C₄.

7. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 3, dans lequel Ar représente un groupe de formule (II) et R₁ représente un atome d'halogène en méta ou un groupe m-trifluorométhyle, R₂ est un groupe OR, S(O)_nR ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, et R' représente un atome d'hydrogène ou un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R', pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), et R₃ représente un atome d'hydrogène ou d'halogène.

8. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 3, dans lequel Ar représente un groupe de formule (II) et R₁ représente un atome d'halogène en méta, R₂ est un groupe OR, S(O)_nR ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, et R' représente un atome d'hydrogène ou un groupe alkyle en C₁-C₁₀, aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R', pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), et R₃ représente un atome d'hydrogène ou d'halogène;

X représente un groupe carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄; et


Y représente un groupe alkyle en C₁-C₄ ou alcoxy en C₁-C₅.

9. Dérivé de 2-arylthiazole de formule (I) ou un de ses sels pharmaceutiquement acceptables selon la revendication 3, dans lequel Ar représente un groupe de formule (II) et R₁ représente un groupe COR'' (où R'' représente un groupe alkyle en C₁-C₁₀, aryle ou aralkyle, non substitué ou substitué);

X représente un groupe carboxyle, alcoxycarbonyle en C₁-C₅, carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C₁-C₄; et

Y représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ou alcoxy en C₁-C₅.


10. Dérivé de 2-arylthiazole ayant la formule (I-a) ci-dessous, ou un de ses sels pharmaceutiquement acceptables, selon la revendication 3:



dans laquelle

R_{1-a} est un groupe alcoxy en C₂-C₈ et R_{2-a} est un groupe nitro;
 R_{1-a} est un groupe alcoxy en C₂-C₈ et R_{2-a} est un groupe trifluorométhyle;
 R_{1-a} est un groupe morpholino, 4-N-méthylpipérazine-1-yle ou pipéridino et R_{2-a} est un groupe nitro;
 R_{1-a} est un groupe morpholino, 4-N-méthylpipérazine-1-yle ou pipéridino et R_{2-a} est un groupe cyano;
 R_{1-a} est un groupe alcoxy en C₂-C₈ et R_{2-a} est un groupe cyano; ou
 R_{1-a} est un groupe benzoyle non substitué ou benzoyle substitué par un ou deux substituants du groupe constitué par un groupe méthyle, un atome de chlore et un groupe méthoxy, et R_{2-a} est un atome d'hydrogène.


11. Dérivé de 2-arylthiazole de formule (I-b) ci-dessous ou un de ses sels pharmaceutiquement acceptables, selon la revendication 4:



dans laquelle

R_{1-b} est un groupe OR ou SR (où R représente un groupe alkyle en C₂-C₈, morpholino, 4-N-méthylpipérazine-1-yle ou pipéridino); R_{2-b} représente un groupe nitro, trifluorométhyle ou cyano, et Y_b représente un atome d'hydrogène ou un groupe méthyle; et

R_{1-b} représente un groupe de formule



(où R_{3-b} représente un groupe phényle non substitué ou substitué; R_{4-b} représente un atome d'hydrogène ou un groupe alkyle en C₁-C₃ et Y_b représente un atome d'hydrogène ou un groupe méthyle).


Revendications pour l'Etat contractant suivant : ES

1. Procédé de préparation de dérivés de 2-arylthiazole ayant la formule



dans laquelle

Ar représente un groupe de formule (II) ci-dessous




dans laquelle au moins un des restes R_1 , R_2 et R_3 est un atome d'hydrogène ou d'halogène ou un groupe nitro, cyano, formyle ou trifluorométhyle; ou un groupe OR, $S(O)_nR$ ou NRR' (où n est un entier de 0 à 2, R représente un groupe alkyle en C_1 - C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué, R' représente un atome d'hydrogène ou un groupe alkyle en C_1 - C_{10} , aryle, aralkyle, alkylcarbonyle, arylcarbonyle ou aralkylcarbonyle, substitué ou non substitué; ou R et R' , pris ensemble avec l'atome d'azote auquel ils sont liés, représentent des atomes qui forment un noyau hétérocyclique de 5 à 7 chaînons substitué ou non substitué), ou un groupe COR'' (où R'' représente un groupe alkyle en C_1 - C_{10} , aryle ou aralkyle, non substitué ou substitué; un groupe hydroxyle; un groupe alcoxy en C_1 - C_{10} , aryloxy ou aralcoxy, non substitué ou substitué; un groupe amino; ou un groupe amino mono- ou disubstitué indépendamment par alkyle en C_1 - C_{10} , amino mono- ou disubstitué indépendamment par aryle, ou amino mono- ou disubstitué indépendamment par aralkyle, substitué ou non substitué; ou un groupe amino cyclique de 5 à 7 chaînons);

X représente le groupe $COOR_a$ où R_a est un groupe alkyle en C_1 - C_4 ; et
 Y représente un atome d'hydrogène ou un groupe alkyle en C_1 - C_4 , alcoxy en C_1 - C_4 , carboxyle, alcoxycarbonyle en C_1 - C_5 , carbamoyle ou aminocarbonyle mono- ou disubstitué par alkyle en C_1 - C_4 ;

à condition que, lorsqu'au moins l'un des groupes R_1 , R_2 et R_3 représente un atome d'halogène ou un groupe alcoxy, alkylamino ou nitro, au moins l'un des deux autres groupes représente un groupe différent de l'hydrogène; et que, lorsqu'au moins l'un des groupes R_1 , R_2 et R_3 est un atome d'halogène et qu'un autre groupe est un atome d'hydrogène, le groupe restant soit un groupe différent d'un atome d'halogène ou d'un groupe alcoxy, alkylamino ou acylamino; et que R_1 , R_2 et R_3 ne soient pas tous en même temps des groupes méthoxy,

caractérisé en ce que les composés sont produits selon la réaction suivante:



où R_a a la définition donnée ci-dessus en relation avec la formule (I), R_1 , R_2 et R_3 ont la définition donnée ci-dessus en relation avec la formule (II), Y a la définition donnée ci-dessus en relation avec la formule (I) et Hal représente un atome d'halogène.

2. Procédé selon la revendication 1, caractérisé en ce que l'on mélange directement le thiobenzamide substitué et un ester alkyle d'un acide 2-halogénoacétyl dans un solvant à une température comprise entre la température ambiante et 200°C.
3. Procédé selon la revendication 2, caractérisé en ce que le mélange réactionnel contient une base.
4. Procédé selon la revendication 3, caractérisé en ce que la base est organique et est choisie parmi la triéthylamine, la pyridine et la diméthylaminopyridine.

EP 0 513 379 B1

5. Procédé selon la revendication 3, caractérisé en ce que la base est inorganique et est choisie parmi le carbonate de potassium anhydre et l'hydroxyde de sodium.
6. Procédé selon l'une quelconque des revendications 2 à 5, caractérisé en ce que le solvant est un hydrocarbure, un éther, un alcool, le N,N-diméthylformamide, le diméthylsulfoxyde ou l'acétonitrile.
7. Procédé selon l'une quelconque des revendications 1 à 6, suivi d'une hydrolyse pour la production de l'acide carboxylique correspondant.

10

15

20

25

30

35

40

45

50

55